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3 ABSTRACT 
Bipolar disorder (BD) is a common and highly heritable disorder, but few susceptibility genes 
have been identified and the underlying biological mechanisms remain poorly understood. 
Epidemiological and molecular genetic studies have provided evidence for genetic overlap 
between BD and other psychiatric disorders, including schizophrenia (SZ). However, we lack 
knowledge on which genetic variants and pathophysiological processes are involved in this 
overlap, and which are confined to one diagnostic category or mechanism. Recent large 
genome-wide association (GWA) studies have detected several novel candidate risk variants 
for BD. In order to confirm these findings, they should be replicated in independent samples, 
and their diagnostic specificity as well as neurobiological effects must be determined. 
 Among these recently identified genetic variants are single nucleotide polymorphisms 
(SNPs) in the genes DGKH, PALB2, ANK3 and CACNA1C. We genotyped 37 DGKH SNPs, 
one PALB2 SNP, three ANK3 SNPs and one CACNA1C SNP in Nordic BD and SZ case-
control samples. SZ cases were included for the purpose of testing for genetic overlap, and ten 
SNPs in the gene BRCA2 were also genotyped, as this gene is functionally related to PALB2. 
To test the hypothesis of increased amygdala activity as a potential genetically conditioned 
underlying mechanism for BD, we measured amygdala activity in a subsample of Norwegian 
individuals genotyped for a CACNA1C risk variant with a functional magnetic resonance 
imaging (fMRI) negative faces paradigm. 
 We confirmed the association between the previously identified PALB2 SNP and BD 
in a meta-analysis, including our Nordic samples and international replication samples, and 
identified one new candidate risk SNP for BD in BRCA2. There was no significant association 
between these SNPs and SZ. 
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 We also replicated the association between two ANK3 SNPs and BD, but found no 
evidence for genetic overlap with SZ.    
 There was no significant association between the DGKH SNPs, including one 
previously identified variant, and BD in our Danish and Norwegian samples. 
 Carriers of the CACNA1C risk allele were found to have increased activity in the left 
amygdala, with indications of a more pronounced effect in BD cases than in SZ cases and 
healthy controls.  
Taken together, these findings further support that PALB2 and ANK3 are BD risk 
genes, and indicate that BRCA2 might be of interest for further investigation. As both PALB2
and BRCA2 are involved in DNA repair, this mechanism could potentially be related to the 
development of BD. Although we found no evidence for DGKH, further studies are needed to 
finally determine the role of DGKH in BD susceptibility. Our findings also support the 
hypothesis that increased amygdala activity is a mechanism underpinning the clinical 
phenotype of BD, and that this mechanism might be conditioned by the CACNA1C risk 
variant. Our findings also implicate ion channelopathy as a putative pathophysiological 
process in BD, taken into consideration that both ANK3 and CACNA1C encode for proteins 
related to ion channel functioning. Furthermore, the current findings indicate a partial genetic 
overlap between BD and SZ, as some of the variants investigated in this study were found to 
be more specific for BD than SZ, while other were associated with the same biological 
mechanism, although more prominent in BD than SZ.  
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4 INTRODUCTION 
4.1 Bipolar disorder 
4.1.1 History of bipolar disorder 
Although states of depression and exaltation were described already in the pre-Hippocratic 
era, Hippocrates (460–337 BC) was probably the first to give a systematic description of 
mania and melancholia. The hypothesis that these two conditions were manifestations of the 
same disease was first proposed by Aretaeus of Cappadocia, a Greek physician of the 1st
century AD (Angst and Marneros, 2001). Aretaeus also suggested that mania and melancholia 
had the same etiology, namely a disturbance of the function of the brain and some other 
organs. The hypothesis of mania and depression being part of the same disease was re-
introduced in 19th century France with the publications of Falret (1851) and Baillarger (1854), 
describing, respectively, the clinical pictures of “folie circulaire” and “folie a` double forme” 
(Haustgen and Akiskal, 2006). In 1899, the German psychiatrist Emil Kraepelin unified all 
types of affective disorders into “manic-depressive insanity”, which he considered to be a 
separate diagnostic entity from “dementia praecox” (Angst and Marneros, 2001), the 
precursor to the current concept of schizophrenia. “Manic-depressive insanity” became split 
anew by the Wernicke-Kleist-Leonhard school into “unipolar disorder” and “bipolar disorder” 
(Kleist, 1953). Further evidence for the distinction between unipolar and bipolar disorders 
was given in the 1960s with publications from Jules Angst, Carlo Perris, and George 
Winokur, who independently showed that there exist clinical, familial and course 
characteristics validating this distinction (Angst and Marneros, 2001). In 1976, Dunner and 
co-workers distinguished depressions with hypomania (bipolar II) from those with mania 
(bipolar I) (Dunner et al., 1976). The currently most commonly used descriptions of bipolar 
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disorder for clinical and scientific purposes are those given in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (First and Tasman, 
2004), including bipolar I disorder, bipolar II disorder, cyclothymic disorder and bipolar 
disorder not otherwise specified (NOS), and in the International Statistical Classification of 
Diseases and Related Health Problems, Tenth Revision (ICD-10), wherein the diagnostic 
category bipolar affective disorder is included (http://www.who.int/classifications/icd/en). 
However, new and broader diagnostic systems, often termed ‘bipolar spectrum 
disorders’ are being discussed. One model suggests several distinct entities, e.g. bipolar 
disorder type III (hypomania in association with antidepressant treatments) and IV 
(depressions superimposed on hyperthymic temperament) in addition to I and II (Akiskal, 
2007), whereas other researchers propose a multi-factor continuum model (Phelps et al., 
2008). 
Common for the above-mentioned models of bipolar disorder, is that the diagnostic 
categories are based on clinical symptomatology, and not on underlying etiological factors. 
Therefore, new neurobiological and genetic findings in bipolar disorder and other psychiatric 
illnesses could provide the basis for a new diagnostic system. This new model could move 
away from the current clinical entities and towards dimensions/categories based on 
knowledge on genetic risk factors and the underlying structures and functions of the brain 
(Craddock and Owen, 2010). 
4.1.2 Clinical picture, course, outcome and treatment 
According to the DSM-IV, bipolar I disorder (BDI) is characterized by the presence of at least 
one manic or mixed episode, whereas the criteria for bipolar II disorder (BDII) is at least one 
major depressive episode and one episode of hypomania. Patients with cyclothymic disorder 
suffer from recurrent episodes of hypomania and dysthymia, although only one episode of 
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hypomania is required to fulfill the diagnostic criteria of cyclothymia. Psychotic symptoms 
may be present in both mania and major depression, but these symptoms must be related to 
and co-occur with the manic or depressive episode. 
Mania is defined as “a distinct period of abnormally and persistently elevated, 
expansive, or irritable mood”, in addition to a list of related symptoms. Hypomania is less 
severe than mania, and can be distinguished from the latter by the absence of marked 
impairment in occupational functioning, usual social activities, relationships with others, the 
necessity for hospitalization, as well as psychotic features. Furthermore, a manic episode must 
last for at least 7 days, whereas a time-period of 4 days is sufficient for an episode to be 
regarded as hypomania. A major depressive episode is defined as a discrete episode of 
persistent and pervasive emotional depression with a set of related symptoms, lasting for a 
period of at least 2 weeks (First and Tasman, 2004). 
Lifetime (and 12-month) prevalences have been estimated to be 1.0% (0.6%) for BDI, 
1.1% (0.8%) for BDII, and 2.4% (1.4%) for subthreshold BD in the USA (N = 9282) 
(Merikangas et al., 2007). In an international study comprising 61392 adults in 11 countries, 
the prevalences were slightly lower. The lifetime (and 12-month) prevalences were found to 
be 0.6% (0.4%) for BDI, 0.4% (0.3 %) for BDII, 1.4% (0.8 %) for subthreshold BD, and 2.4% 
(1.5 %) when added together. Furthermore, three-quarters of patients with the above-
mentioned diagnoses had at least 1 other disorder, of which anxiety disorders were the most 
common conditions (Merikangas et al., 2011). The authors of this study also reported that the 
severity, impact, and patterns of comorbidity were remarkably similar in different countries 
across the globe, despite some variation in prevalence rates. 
 Most recent studies have found age at onset of BD to be in adolescence and young 
adulthood (Leboyer et al., 2005;Perlis et al., 2004). In a study comprising 2839 patients with 
BD, the median age at onset was 17.5 years and the average age at onset was 19.8 years 
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(Kupfer et al., 2002). A study of Norwegian in-patients diagnosed with BD (N = 146) found 
the mean age at first affective episode to be 20.2 years (Morken et al., 2009), while a study of 
Norwegian out-patients with BD (N = 225) reported the average age at onset to be  22.8 years 
(Larsson et al., 2010). Early age of onset in BD has been found to be associated with long 
delay to first treatment, more episodes, comorbidities and rapid cycling, as well more severe 
mania, depression, and fewer days well (Leverich et al., 2007). 
With regards to clinical course and outcome, the McLean/Harvard cohort I (N = 75) 
found that 28 % of the BD patients were episode-free and 28 % had experienced >3 relapses 
after four years follow-up (Tohen et al., 1990). As for the functional outcome in this study, 19 
% of the patients in this study were unable to live independently and 28 % were unable to 
study or work after four years (Tohen et al, 1990). Another prospective cohort study (N = 
186) found that 82 % of BD patients experienced relapse 7 years after recovery. The 
corresponding number for those whose index episode had been followed by at least 3 years 
without symptoms was 69.9 %. For those who were treated with lithium prophylaxis, 70% 
experienced relapse within 5 years of recovery (Coryell et al., 1995). Among the reported 
poor prognostic factors for BD are substance abuse (Nolen et al., 2004;Weiss, 2004), family 
history of substance abuse (Nolen et al., 2004), rapid cycling (Dittmann et al., 2002;Nolen et 
al., 2004), poor occupational functioning at study entry (Nolen et al., 2004), and past 
comorbid attention-deficit disorder (Nierenberg et al., 2005). 
Patients with BD have been found to have an increased mortality ratio compared to the 
general population. Suicide and cardiovascular disease are two of the most important factors. 
A Danish study assessing all patients admitted to a psychiatric hospital from 1973 to 1993 (N 
= 54103) found standard mortality ratio (SMR) to be significantly increased compared to the 
general population (1.8 for women and 2.2 for men). For the BD patients included in this 
study, SMR for suicide was 20.3 for women and for 18.1 men (Hoyer et al., 2000). A 
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Norwegian study found the prevalence of cardiovascular risk factors in patients suffering 
from BD to be approximately twice that of the general population, and not significantly 
different from the prevalence in SZ (Birkenaes et al., 2007). 
Cognitive dysfunction in patients with BD is well documented, and there is evidence 
for cognitive impairment also in the euthymic phase (Robinson et al., 2006). One recent study 
found the severity of neurocognitive deficits in patients suffering from BD and SZ to be 
dependent on history of psychosis rather than diagnostic category and subtype (Simonsen et 
al., 2011). The same research group found patients with BD I to perform significantly poorer 
on certain neurocognitive measures than those suffering from BD II (Simonsen et al., 2008). 
 The pharmacological treatment of BD usually comprises Lithium, anticonvulsants, 
typical and atypical antipsychotics, antidepressants and benzodiazepines. Treatment 
recommendations are can be divided into three categories based on phases of the illness, i.e. 
the acute, continuation and maintenance phase. The acute phase can be further divided into 
those predominated by mania/hypomania and depression. Randomized clinical trials (RCTs) 
with sufficient power (> 0.8) to detect statistically significant differences (P < 0.05) (category 
A evidence) have found that 8 dopamine-blocking agents (Olanzapine, Ziprasidone, 
Quetiapine, Risperidone, Haloperidol, Aripiprazole Paliperidone and Asenapine) and 3 non-
dopamine-blocking agents (Lithium, Valproate and Carbamazepine) have an effect on mania. 
For depression, Lamotrigine, Olanzapine and Quetiapine monotherapy meet the same 
empirical criteria as listed above, as well as combination therapy with Olanzapine and 
Fluoxetine (Sachs et al., 2011). With regards to the maintenance phase, Lithium, Valproate, 
Olanzapine, Ziprasidone, Quetiapine, Risperidone, Aripiprazole, Lamotrigine were found to 
prevent recurrence of acute episodes significantly (Sachs et al., 2011). 
 Among the non-pharmacological treatments, Electro-convulsive therapy (ECT) has a 
documented effect on depressive as well as manic episodes in patients with BD (Taylor, 
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2007). Several kinds of psychotherapy have been investigated in intervention studies in BD, 
including psychoeducation, cognitive-behavioural, interpersonal and social rhythm and 
psychoanalytic therapy (Jones, 2004). Individual cognitive-behavioural therapy (CBT) has 
been shown to reduce symptoms and risk of relapse and improve social functioning (Jones, 
2004), whilst pscychoeducation has been associated with increased knowledge of 
the disorder, improvement of adherence and reduced risk of relapse (Rouget and Aubry, 
2007). However, the goal of these forms of treatment is to teach the patient how to live with 
the disorder rather than to gain insight. Moreover, these approaches are designed to be used as 
adjuvant therapy to medication (da Costa et al., 2010;Rouget and Aubry, 2007). 
4.1.3 Etiology and pathophysiology 
The hypothesis that certain psychiatric illnesses are inherited brain disorders was already 
proposed by the Swiss physician Paracelsus in 1520, and the ‘hereditary taint’ of manic-
depressive illness was estimated to be about 80 % by the German psychiatrist Emil Kraepelin 
in 1899 (Goodwin and Jamison, 2007). These hypotheses have to a large degree been 
confirmed by more recent studies. Family, twin and adoption studies from the 20th century 
have provided evidence that BD is a highly heritable disorder (Smoller and Finn, 2003). 
While the studies conducted in the first half of this century often included both unipolar and 
bipolar cases, studies undertaken after 1960 have investigated the familial clustering and 
heritability of BD specifically. Whereas the family studies have shown that BD has a 
tendency to run in families, the twin studies suggest that this phenomenon is due to genetic 
rather than environmental factors (Smoller and Finn, 2003). In a meta-analysis of family 
studies comprising more than six thousand BD relatives, the weighted summary morbid risk 
estimate for probands was 8.7 (Smoller and Finn, 2003). This estimate is in line with the 
results from a recent Swedish epidemiological study of more than nine million individuals, 
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including over thirty-five thousand BD patients and forty thousand SZ patients, which 
reported that first-degree relatives of probands with BD had a relative risk of 7.9 for BD. 
Interestingly, these probands also had significantly increased relative risk for SZ, and vice 
versa (Lichtenstein et al., 2009). 
Twin studies comparing concordance rates for monozygotic (MZ) and dizygotic (DZ) 
twin pairs have made it possible to assess the heritability of BD more accurately than family 
studies, as MZ twin pairs share 100 % of their genetic variation, whilst DZ twin pairs share 50 
%. Thus, assuming shared environment for MZ and DZ twin pairs, any differences in 
concordance rates for a given disease between MZ and DZ twin pairs, is likely to result from 
more genetic similarity of the MZ than DZ twin pairs. There are several ways to estimate 
heritability based on twin studies. One of the simplest methods is ‘Holzinger’s heritability’, 
which calculates the heritability with this formula: (Concordance rate in MZ twins – 
concordance rate in DZ twins) divided by (100 – concordance rate in DZ twins) (Goodwin 
and Jamison, 2007). Based on several twin studies, the heritability for BD has been estimated 
to be in the range of 60–85%, and the same studies provide little evidence that shared 
environment plays a large role (Barnett and Smoller, 2009). However, the concordance rates 
for MZ twins has never been found to be 100 %, which means that environmental and/or 
epigenetic factors probably increases the risk for developing BD in individuals with high risk 
genetic variants. 
 Adoption studies might distinguish environmental from genetic factors when 
comparing the rates of BD in biological and adoptive family members. Unfortunately, there 
are few such studies for BD (Smoller and Finn, 2003). One adoption study (N = 299 parents) 
found the frequency of affective illness (comprising bipolar, unipolar, schizoaffective, and 
cyclothymic disorders) to be significantly higher in the biological parents (32%) than in the 
adoptive parents (12%) of BD cases (Mendlewicz and Rainer, 1977), a finding which adds to 
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the evidence gained from family and twin studies that genetic factors are important in the 
development of BD. 
 Despite the high heritability estimates for BD, few susceptibility genes have been 
unambiguously identified and the neurobiological mechanisms remain poorly understood 
(Nothen et al., 2010). Nevertheless, there are interesting findings on different neurobiological 
and clinical levels in BD, which we will discuss briefly in the following section. 
Post mortem studies have shown structural abnormalities in the brains of BD patients. 
There is evidence of decreased neuron and glia density and decreased size of neurons in 
frontal and subcortical areas. It has been hypothesized that this may result from increased 
apoptosis and oxidative stress in BD (Gigante et al., 2011), but mitochondrial dysfunction 
(Kato, 2008), excitotoxicity and neuroinflammation (Rao et al., 2010) and genetically 
influenced abnormalities in synaptic and neuronal plasticity (Schloesser et al., 2008) are also 
suggested as putative underlying mechanisms. 
Several imaging studies have reported structural and functional brain abnormalities in 
BD patients. A recent large structural magnetic resonance imaging (sMRI) study (N = 139 BD 
cases, 173 SZ spectrum cases and 207 healthy controls) found no cortical thinning in subjects 
with BD compared with healthy controls, but a subgroup of patients with BDI were found to 
have cortical thinning in the frontal lobes, superior temporal and temporo-parietal regions. 
Furthermore, subcortical volume reductions for BD subjects were reported bilaterally in the 
hippocampus, in the left cerebellar cortex, the left thalamus, the right nucleus accumbens and 
the brainstem. Additionally, the authors found substantial ventricular enlargements (Rimol et 
al., 2010). A recent meta-analysis of functional magnetic resonance imaging (fMRI) studies 
reported over-activation of amygdala, thalamus and striatum, as well as less consistent 
evidence for increased activation in the dorsolateral and ventrolateral cortex (Cerullo et al., 
2009). Another MRI finding in the brain possibly related to pathophysiological processes in 
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BD is hyperintensities. In a meta-analysis of 27 studies, hyperintensities were significantly 
more prevalent in BD subjects than healthy controls, with the most pronounced findings in 
adolescents and children. These hyperintensities were most often localized in the 
deep white matter and subcortical grey matter. However, there was no significant difference 
between hyperintensities observed in BD, and those found in unipolar depression and SZ. And 
the role of these hyperintensities in BD remains elusive (Beyer et al., 2009). Furthermore, 
medication status has been shown to influence the structure and function of certain brain 
regions. For example, the use of lithium has been associated with volumetric increase in the 
medial temporal lobe and anterior cingulate gyrus (Emsell and McDonald, 2009) and with 
increased total grey-matter volume (Moore et al., 2000). 
An animal study found the administration of lithium to be associated with increased 
Neuropeptide Y in the hippocampus and striatum and decreased corticotropine-releasing 
hormone in maternally deprived rats (Husum and Mathe, 2002), a finding which might be 
interpreted as an indication that lithium counteracts the physiological effects on a state similar 
to clinical depression. 
Among other noteworthy findings from animal studies on psychopharmacological 
drugs, are the blocking effect of fluoxetine, an SSRI (selective serotonin reuptake inhibitor), 
on the downregulation of cell proliferation in mice resulting from inescapable shock in a 
learned helplessness model of depression (Malberg and Duman, 2003). Lithium, 
carbamazepine and valproic acid have been found to inhibit the collapse of sensory neuron 
growth and increase growth area, possibly by inositol depletion (Williams et al., 2002). 
Moreover, the protein p11, which interacts with the serotonin 1B receptor 5-
hydroxytryptamine (5-HT1B) receptor, is reported to be increased in rodent brains with the use 
of ECT and antidepressants, and to be decreased in an animal model of depression and in 
brain tissue from depressed patients. p11 knockout mice exhibit a depression-like phenotype 
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and have reduced responsiveness to 5-HT1B receptor agonists and reduced behavioral 
reactions to an antidepressant (Svenningsson et al., 2006). 
As neurotransmittors are involved in the pharmacological treatment of BD, it has been 
hypothesized that dysfunctions in neurotransmission may be part of the neurobiological 
mechanisms. A particular focus has been put on glutamatergic abnormalities. A review article 
reported findings from magnetic resonance spectroscopy (MRS) studies on glutamate and 
glutamine. The authors found a consistent pattern of reduced level of mixture signal from 
glutamate and glutamine (Glx) in MDD and elevations of Glx in BD. Additionally, there was 
evidence of a reduced glutamine/glutamate ratio in depression and an elevated 
glutamine/glutamate ratio in mania. This might, according to the authors, result from reduced 
glutamate conversion to glutamine by glial cells (Yuksel and Ongur, 2010).  
Glutamate abnormalities have also been hypothesized to play a role in certain types of 
epilepsy (Eid et al., 2008). Further evidence supporting common pathophysiological 
mechanisms in BD and epilepsy include comorbidity between epilepsy and mood disorders, 
the episodic pattern of both diseases, and the fact that the kindling phenomenon and 
modifications in neurotransmitters, voltage-gated ion channels and second-messenger systems 
have been reported for both disorders (Mula, 2010).
The episodic outburst of manic/hypomanic and depressive episodes in BD have led to 
research on possible trigger mechanisms. There is some evidence that abnormal 
catecholamine levels, up-regulation of neurotrophic and neuroplastic factors, hypothalamic-
pituitary-adrenal axis (HPA) hyperactivity, circadian rhythms and tricyclic antidepressants 
might trigger mood switches in BD (Salvadore et al., 2010). 
As for dopamine and serotonin synaptic transmission, in vivo imaging of synaptic 
function in BD patients have yielded inconsistent results (Nikolaus et al., 2009). 
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Abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis have been studied in 
mood disorders, with consistent evidence for elevated cortisol and corticotrophin releasing 
hormone (CRH) levels and hypofunction of the glucocorticoid receptor (GR) in depression 
(Zunszain et al., 2011). However, there is more inconsistency in the corresponding features in 
BD, although increased response to dexamethasone-suppression test in BD cases compared to 
healthy controls has been reported (Watson et al., 2004). Furthermore, it is unknown whether 
these observed HPA abnormalities represent an underlying factor involved in the 
pathophysiology of the disorder or whether it is a result of disease-related processes. 
As for the potential environmental risk factors, a kindling hypothesis has been 
proposed, in which stressful life events trigger initial episodes, with successive episodes 
becoming less dependent of stressors and may occur autonomously (Post, 1992). Childhood 
trauma has been suggested as a possible environmental risk factor in BD. In a cohort study 
comprising 100 patients with BD, histories of severe childhood abuse were identified in 51%, 
a finding which indicates that childhood abuse might increase the risk of developing BD in 
individuals with genetic susceptibility for this disorder (Goldberg and Garno, 2005). 
4.2 Human genetics 
The DNA double-helix structure was discovered in 1953, by Francis Crick and James D. 
Watson, and in 1957 Crick presented the central dogma of molecular biology, describing the 
relationship between DNA, RNA, and proteins. In February 2001, the publicly funded 
International Human Genome Sequencing Consortium (IHGSC) (Lander et al., 2001) and the 
private company Celera Genomics (Venter et al., 2001) each reported the first draft sequences 
of the human genome. Two years later a more comprehensive version was made available by 
the IHGSC, containing 2.85 billion nucleotides and covering ~99% of the euchromatic 
genome (International Human Genome Sequencing Consortium, 2004). On the basis of these 
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investigations, it has been estimated that the human genome encodes 20,000-25,000 protein-
coding genes and that the total length of the euchromatic genome covered by coding exons is 
~1.2% (International Human Genome Sequencing Consortium, 2004). 
 Human to human genetic variation is estimated to be only about 0.2%, in other words, 
human genetic similarity is ~99.8 %. Of these 0.2 % differences, approximately 0.12 % have 
been found to be structural variants and 0.08 % single nucleotide variants (Sebat, 2007). 
Structural variants can be further classified as inversions, insertion-deletions and Copy 
Number Variants (CNVs), whereas single nucleotide variants with a minor allele frequency 
(MAF) above 1% are referred to as single nucleotide polymorphisms (SNPs). The total 
number of SNPs in the human genome has been estimated to be about 11 millions (Kruglyak 
and Nickerson, 2001). 
Newly developed methods, like the DNA microarray (DNA chip) technology, have 
enabled the investigation of up to 1 million genetic variants at a steadily lower consumption 
of time and financial expenses. When testing for association between a certain SNP and a 
disease, one can either use a direct or indirect approach. A direct approach hypothesizes that 
the actual SNP is the disease-causing variant, for example by altering the protein structure or 
the expression of the protein, whereas an indirect approach aims at maximizing the actual 
SNPs` ability to collect information form surrounding SNPs, of which one or more may be 
disease-causing. 
A SNP with a high ability to capture information from other SNPs is called a 
‘tagSNP’. In order to gain information on other SNPs, the actual SNP and the other SNP must 
be in strong Linkage Disequilibrium (LD). LD denotes the phenomenon of two or more 
alleles at different loci having a stronger association than what we could expect to occur if 
they were randomly combined. A high LD usually means that the two SNPs are localized 
within the same haplotype block (the SNPs are inherited together, no recombination has 
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occurred between them). The degree of LD is expressed by either D’ (0  D’  1) or by r2 (0 
r
2  1). If D’/r2 = 1, the two SNPs are considered to be in complete/perfect LD, while if D’/r2
= 0, the two loci are totally independent of each other. On the basis of LD, tagSNPs can be 
used as proxies for other SNPs that are not genotyped. The International HapMap Project is 
an available database for assessing LD between SNPs and picking tagSNPs 
(www.hapmap.org). The DNA samples for the HapMap come from 270 individuals from four 
populations: the Yoruba people in Ibadan, Nigeria (30 trios), Japanese in Tokyo (45 unrelated 
individuals), Han Chinese in Beijing (45 unrelated individuals), and from U.S. (residents with 
ancestry from Northern and Western Europe, collected by the Centre d'Etude du 
Polymorphisme Humain (CEPH)) (30 trios). More than 1.1 million SNPs were genotyped in 
phase I of the project (Thorisson et al., 2005), phase II included over 3.1 million SNPs (Frazer 
et al., 2007), and phase III characterized 1.6 million SNPs in 1,184 individuals from 11 
populations (Altshuler et al., 2010). 
 In 2008 the ‘1000 Genomes Project’ was launched, a project which aims at acquiring 
accurate haplotype information on all forms of DNA polymorphism in several human 
populations. By combining low-coverage whole-genome sequencing, array-based genotyping 
and deep targeted sequencing in 2500 individuals from five large regions of the world 
(Europe, East Asia, South Asia, West Africa and the Americas), the goal is to gain 
information on 95% of variants with an allele frequency of 1% or higher. The pilot phase of 
this project has already been released (The 1000 Genomes Project Consortium, 2010). 
   
4.3 Bipolar disorder and genetics 
Although heritability estimates of BD are high, no risk genes or genetic regions have been 
firmly established for this disorder. Epidemiological studies have shown that BD is a complex 
illness with many risk variants involved (Craddock et al., 1995). A ‘common disease-common 
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variant’ (CDCV) model has been assumed, in which several common variants (SNPs), each 
conferring a small risk, must interact to give rise to the disorder (Barnett and Smoller, 2009). 
But rare variants (CNVs) with larger effect sizes, as well as multiple rare variants with small 
effect sizes have also been hypothesized to be implied in the genetic susceptibility for BD 
(Lee et al., 2012) (Figure 1). 
        Effect size 
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            frequency 
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Figure 1. Effect size and allele frequency determine which study approach is best suited for detecting 
risk genetic variants (modified after Owen et al., 2009). 
4.4 Study design and results 
Susceptibility genes for BD have been sought with three major approaches (Serretti and 
Mandelli, 2008): 
• Functional candidate approach  
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• Positional candidate approach  
• Genome-wide association (GWA) studies 
4.4.1 Functional candidate approach  
The functional candidate approach is based on a priori hypotheses and knowledge on 
physiological alterations of the disease, pharmacological studies and animal models (Serretti 
and Mandelli, 2008). Selected candidate genes/genetic variants are genotyped in cases and 
controls, and statistical tests undertaken to assess whether these genetic variants are 
overrepresented in cases. If a statistical significant association is found, this increases the 
likelihood of the actual genetic variant being a disease-causing variant. The early candidate 
gene studies had a particular interest in the serotonin, dopamine, and noradrenaline 
neurotransmitter systems, as these are involved in the pharmacological treatment of BD. 
Several studies investigated genes encoding catechol-O-methyltransferase (COMT), 
monoamine oxidase A (MAOA) and the serotonin transporter (5HTT), but with inconsistent 
results. The same holds for studies on genes involved in circadian rhythm and BD (Craddock 
and Sklar, 2009). Due to the clinical, and proposed genetic, overlap between BD and 
schizophrenia (SZ), several studies have assessed the potential involvement of SZ risk genes 
in BD, including disrupted in schizophrenia (DISC1), the G72/G30 locus (D-amino acid 
oxidase activator [DAOA]), Neuregulin 1 (NRG1) and brain derived neurotrophic factor 
(BDNF). However, both positive and negative findings have been reported, as is the case with 
several other candidate genes, including those encoding dystrobrevin binding protein 1 
(DTNBP1), tryptophan hydroxylase 2 (TPH2), dopamine receptor D4 (DRD4) and solute 
carrier family 6 (neurotransmitter transporter, dopamine), member 3 (SLC6A3) (Craddock 
and Sklar, 2009). 
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4.4.2 Positional candidate approach 
The positional candidate approach is based on findings from linkage studies and selection of 
genes located in regions associated with BD. Linkage studies investigate which regions are 
co-inherited with the disease by comparing unaffected and affected family members with 
respect to genetic markers across the genome. Many linkage studies on BD have been 
conducted, suggesting several areas of the genome being co-inherited with the disorder, but 
again without consistent replications between studies (Barnett and Smoller, 2009). This lack 
of robust findings indicates that no single gene or genetic region has a major effect on 
increasing the risk for developing BD. 
4.4.3 Genome-wide association (GWA) studies 
In the recent couple of years, several GWA studies have been performed in BD case-control 
samples. GWA studies can investigate millions of markers across the genome, without an a 
priori hypothesis. Such an ‘agnostic’ approach seems meaningful for BD, as no 
pathophysiological pathways have been identified. Thus, GWA studies, if successfully 
conducted and interpreted, could be hypothesis-generating for new potential neurobiological 
mechanisms as well as for drug development. However, with such a high number of genetic 
variants, GWA studies impose major statistical challenges with respect to multiple testing 
correction. Since 2007, several GWA studies on BD have been published, with larger samples 
and more significant findings than experienced before in psychiatric genetics, although the 
effect sizes have been found to be very low for each variant. The largest published BD GWA 
studies at the time when the studies in this thesis were planned and performed, includes the 
Wellcome Trust Case-Control Consortium (WTCCC) study (N = 1868 cases and 2938 
controls of British descent), finding strong association between a SNP in PALB2 (partner and 
localizer of BRCA2) and BD (WTCCC 2007), a German/American study (N = 1233 cases and 
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1439 controls) reporting association between a SNP in DGKH (diacylglycerol kinase eta) and 
BD (Baum et al., 2008), an American/British study (N = 1461 BDI cases and 2008 controls in 
discovery sample) with MYO5B (myosin5B) and TSPAN8 (tetraspanin-8) as the top hits 
(Sklar et al., 2008), and a large collaborative study (N = 4387 cases and 6209 controls of 
European descent) identifying ANK3 (ankyrin3) and CACNA1C (alpha 1C subunit of the L-
type voltage-gated calcium channel) as BD candidate genes (Ferreira et al., 2008). Of these 
findings, ANK3 and CACNA1C have been replicated (Sklar et al., 2008;Lee et al., 
2011;Schulze et al., 2009;Scott et al., 2009;Smith et al., 2009). 
Furthermore, during the current PhD work a large multi-center international GWA study 
(Psychiatric GWAS Consortium (PGC)) has been initiated for psychiatric disorders, including 
autism (AUT), Attention Deficit Disorder (ADD), BD, major depressive disorder (MDD) and 
SZ (PGC 2009). 
An overview on available BD GWA studies can be found at 
(http://www.genome.gov/GWAStudies). 
Taken together, molecular genetic studies have shown that BD is a polygenic disorder 
where each variant has a small effect for developing the disorder. Due to small effect sizes, 
large numbers of cases and controls are needed to detect true risk variants.  
Recent GWA studies have yielded more consistency with regards to highly significant 
findings, but we still lack knowledge on the potential multitude of genetic risk variants, 
pathophysiological pathways, genetic and gene-environment interactions for BD. Further, in 
contrast to SZ, few rare structural variants (CNVs) have been identified for BD (Lee et al., 
2012). 
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4.5 Pleiotropy and bipolar disorder 
‘Pleiotropy’ denotes the phenomenon of one gene (or one genetic variant) affecting multiple 
traits (Wagner and Zhang, 2011). A pleiotropic effect has been hypothesized for genetic 
variants conferring risk to severe psychiatric disorders, including BD and SZ, and recent 
evidence seems to support this hypothesis. Epidemiological studies have found overlap in 
heritability between BD and SZ (Lichtenstein et al., 2009), and molecular genetic studies have 
identified overlapping risk variants for these two disorders (Moskvina et al., 2009). A recent 
report found that six out of eight of the most robustly associated loci for BD and SZ, were 
significantly associated with both disorders (Williams et al., 2011). There is also evidence for 
genetic overlap between BD and major depressive disorder (MDD). In a meta-analysis 
combining and comparing results from a GWAS on BD (N = 4387 BD cases and 6209 
controls) (Ferreira et al., 2008) with a GWAS on MDD (N = 1695 MDD cases and 1761 
controls) (Sullivan et al., 2009), variants in CACNA1C attained genome-wide significant 
association in the combined sample (Liu et al., 2010). 
However, the concept of pleiotropy is particularly challenging when investigating 
psychiatric disorders, as there are no quantifiable bio-markers unambiguously distinguishing 
one psychiatric phenotype from another. Thus, the finding of common risk genes for BD, SZ 
and MDD might as well be interpreted as an evidence for floating diagnostic borders, and the 
proposed support for the pleiotropy hypothesis could result from a flawed diagnostic system 
rather than from multiple distinct effects of each genetic variant. 
It is interesting in this respect that Emil Kraepelin, although suggesting that manic-
depressive illness and dementia praecox were separate diagnostic entities, also expressed 
doubt about this distinction himself:  “No expert will deny that cases which cannot be 
classified safely are disturbingly frequent… We will have to get used to the idea that all signs 
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are insufficient to delineate manic–depressive insanity from schizophrenia… and that overlap 
occurs’’ (quoted in Angst, 2002). 
Several models challenging the current DSM-IV and ICD-10 criteria for severe 
psychiatric diagnostic categories have been proposed, including the pre-kraepelinian ‘unitary 
psychosis’ model, two or more overlapping categories and a floating continuum model 
(Craddock et al., 2009). 
         
         
Unitary psychosis     
Two non-overlapping     
disorders 
Two overlapping disorders 
Three or more 
overlapping disorders 
Continuum 
  
Bipolar end of spectrum     Schizophrenia end of spectrum 
Figure 2. Possible models describing the relationship between bipolar disorder and schizophrenia 
(modified after Craddock et al., 2009) 
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To identify the best-fitting of these models, genetic cross-disorder and endophenotype 
studies could prove helpful. Hopefully, such studies might answer the questions of which, if 
any, genetic variants confer risk solely to BD, which increase the risk of developing broader 
spectrums of diagnostic categories, and by which mechanisms. 
4.6 Endophenotypes and subphenotypes 
An endophenotype is defined as ‘a measurable component unseen by the unaided eye along 
the pathway between disease and distal genotype’ (Gottesman and Gould, 2003). 
Furthermore, an endophenotype must fulfill certain criteria: 
1. The endophenotype is associated with illness in the population. 
2. The endophenotype is heritable. 
3. The endophenotype is primarily state-independent (manifests in an individual whether 
or not illness is active). 
4. Within families, endophenotype and illness co-segregate. 
In psychiatry an endophenotype may be neurophysiological, biochemical, endocrinological, 
neuroanatomical, cognitive, or neuropsychological (Gottesman and Gould, 2003). 
 In BD many attempts have been performed to identify an endophenotype which lies 
closer to the genetic variation than the clinical phenotype does. These markers include mRNA 
expression, brain structure observed with sMRI, brain function assessed with fMRI, 
histological anomalies investigated with postmortem studies, neurotransmission with Positron 
Emission Tomography (PET), neurocognition validated with neurocognitive testing, 
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personality traits assessed with testing, electromagnetic activity with electroencephalography 
(EEG) and other biomarkers extracted from blood samples. 
 As no neurobiological mechanisms or risk genes are firmly identified for BD, this is 
also true for endophenotypes. But the endophenotype strategy is still an emerging field in 
psychiatric genetics, which will hopefully develop as we gain more insight form genetic 
association studies and studies on neurobiological aspects of BD and psychiatric disorders in 
general. One approach in endophenotype studies is to look for association between previously 
identified genetic variants and putative endophenotypic markers for the disease. An example 
of this is a study investigating the possible association between variants in the CACNA1C
gene previously identified from BD GWAS studies, and brain volume as assessed with 
structural MRI, finding evidence of altered brainstem volume (Franke et al., 2010). Another 
endophenotype approach is to look for association between genetic variants and an 
endophenotypic marker previously identified for the disease. A hypothetical example of this is 
using amygdala activation as a phenotype in a GWA study, to identify genetic variants 
associated with abnormal amygdala activation. 
 A subphenotype is a symptom or group of symptoms which constitutes a small 
spectrum of the total diagnostic phenotype, for example BD with psychosis (Lett et al., 2011). 
Considering the fact that our current diagnostic systems are based solely on a pattern of 
symptoms rather than on an underlying etiology, it is plausible that genetic variants encode 
proteins that in turn give rise to symptoms not easily fitting into the categories of the 
psychiatric nosology. Attempts at identifying such subphenotypes have been and are being 
performed, either with a case-control or a case-case design, but like the rest of molecular 
genetic studies on BD – with few, or none, robust findings. 
 To summarize, no endophenotypes or subphenotypes have been firmly identified for 
BD. But new findings form major BD GWA case-control studies enable the investigation of 
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association between recently identified genetic risk variants and potential sub- and 
endophenotypes. 
  
4.7 Amygdala activity in bipolar disorder 
Emotional dysregulation is part of the BD phenotype, manifesting as mania, hypomania and 
depression. Thus, it has been hypothesized that abnormal activity in the limbic system is 
involved in BD pathophysiology (DelBello et al., 2004). In particular, amygdala has been 
studied extensively as a potential endophenotype. 
The amygdalae are complexes of grey matter situated in the medial temporal lobes and 
considered part of the limbic system. Three major groups of nuclei have been identified, with 
projections to various cortical and subcortical structures. Animal studies, clinical observations 
and imaging studies have shown that amygdala plays a role in memory and processing of 
emotions, including negative and positive conditioning (Baxter and Murray, 2002;Johansen et 
al., 2011). More recently, it has been hypothesized that amygdala is a ‘detector of relevance’ 
in a broad category of biologically relevant stimuli, and that, through evolution, social 
relevant events have become the predominant area of amygdala`s domain of influence 
(Sander et al., 2003). 
Volumetric studies have yielded inconsistent results with respect to altered amygdala 
size in BD (Kempton et al., 2008). One recent mega-analysis including 321 patients with BD I 
and 442 healthy control subjects, found amygdala volume to be increased in patients treated 
with lithium compared to controls and patients not treated with lithium (Hallahan et al., 2011), 
whereas another large study with 139 BD patients and 207 healthy controls found no change 
in amygdala volume in BD (Rimol et al., 2010). 
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As for the amygdala activity in BD, a meta-analysis comprising 65 fMRI studies of 
1074 healthy volunteers and 1040 BD cases, found evidence for amygdala over-activation in 
euthymic BD patients compared with healthy controls (Chen et al., 2011). This over-
activation was observed mainly during emotional, and not during cognitive, paradigms. 
Decreased frontal activity was observed during both emotional and cognitive paradigms.  
However, it is unclear whether this abnormal activation is a genetically conditioned 
pathophysiological mechanism in BD, or an effect of other disease-related processes. 
Molecular genetic studies could play an important role in addressing this question.  
   
4.8 Aims of the thesis 
The overall aim of the thesis was to gain insight in the molecular genetic basis of BD, by 
investigating for association between candidate genes and disease phenotypes in Nordic case-
control samples. In study I – III, we investigated the potential association between previously 
identified BD candidate risk genetic variants and BD, in our case-controls samples. The 
genetic variants studied were all selected on the basis of findings from large recent GWA 
studies on BD. As GWA studies are hypothesis-free in terms of gene functions and 
mechanisms, it was of particular interest that some of the genes found to be strongly 
associated with BD in these studies, are known to be expressed in the brain, where their 
expressed proteins have functions related to ion channel functioning (ANK3, CACNA1C) and 
to a lithium sensitive phosphatidyl inositol pathway (DGKH). On the basis of this statistical as 
well as pathophysiological evidence, it would increase the likelihood of these variants being 
truly involved in the pathophysiological processes of BD, if these findings could be replicated 
in our independent Nordic population. 
The secondary aims of the thesis were: 
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1. To assess the potential pleiotropic effect of these genetic variants 
2. To investigate if a BD risk variant increases amygdala activity, and to explore the 
potential diagnostic specificity of this effect. 
The aim of Study I was to investigate the association between genetic variants in 
diacylglycerol kinase eta (DGKH) and BD in a Scandinavian BD case-control sample. 
The aim of Study II was to confirm the association between a genetic variant in PALB2
(partner and localizer of BRCA2) and BD in a Scandinavian case-control sample, and to test 
for potential genetic overlap with SZ. We also wanted to assess the potential association 
between variants in the functionally related gene BRCA2 (breast cancer 2, early onset) and BD 
and SZ. 
The aim of Study III was to corroborate the association between genetic variants in ankyrin 3 
(ANK3) and BD and to test for genetic overlap with SZ in Nordic case-control samples. 
The aim of Study IV was to assess the potential effect of CACNA1C SNP rs1006737 on 
amygdala activity, and to determine the diagnostic specificity of this effect in Norwegian BD 
and SZ cases and healthy controls. 
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5 MATERIAL AND METHODS 
5.1 Study samples 
5.1.1 SCOPE bipolar disorder and schizophrenia case-control samples 
The SCOPE (Scandinavian Collaboration on Psychiatric Etiology) sample used in the studies 
in this dissertation comprises individuals included in the Norwegian TOP (Thematically 
Organized Psychosis) study, the Norwegian BRAIN (Bipolar Research And Innovation 
Network, Norway) study, the Swedish Human Brain Informatics (HUBIN) study and the 
Danish Psychiatric Biobank. 
The Norwegian TOP sample 
The TOP study is an ongoing translational research study recruiting patients and healthy 
control subjects from several hospitals in the Oslo area. To be included in the TOP study, 
patients have to be between 18 and 65 years old, speak a Scandinavian language and fulfill the 
diagnostic criteria for a SZ spectrum or BD spectrum disorder according to DSM-IV. 
Individuals with serious brain damage or developmental disorder are excluded. Diagnostic 
assessment is performed by trained psychologists, psychiatrists or MDs specializing in 
psychiatry, of whom all participate in diagnostic meetings supervised by professors in 
psychiatry. The studies in this dissertation include patients with bipolar I disorder (BDI), 
bipolar II disorder (BDII), bipolar disorder not otherwise specified (BD NOS), schizophrenia 
(SZ), schizoaffective disorder (SZA), schizophreniform disorder (SZF) and persistent 
delusional disorder according to DSM-IV using the Structural Clinical Interview for DSM-IV 
(SCID) (Spitzer et al., 1992). Reliability of the diagnostic assessment in the TOP study has 
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been tested, and the overall agreement for the DSM-IV diagnostic categories tested was 82 % 
and the overall Kappa 0.77 (95 % CI: 0.60-0.94). 
Clinical, neurocognitive and psychosocial assessment was undertaken during an initial 
interview. In this interview information on length of education, age of onset, number of 
relapses, medication status, alcohol and illegal substance abuse was obtained. Patients 
included in the studies in this thesis were assessed clinically with Young Mania Rating Scale 
(YMRS) (Young et al., 1978), Inventory of Depressive Symptoms (IDS) (Rush et al., 1996), 
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), Global Assessment of 
Functioning – symptom score (GAF-S) and Global Assessment of Functioning – function 
score (GAF-F) (First and Tasman, 2004), and neurocognitively with the Wechsler 
Abbreviated Scale of Intelligence (WASI) (Brager-Larsen et al., 2001). Alcohol abuse and use 
of illegal substances during the last six months was measured with the Evaluating Substance 
Abuse in Persons with Severe Mental Disorders scale (Drake, 1996). On the day of fMRI 
scanning, patients underwent an abbreviated re-interview including YMRS, IDS and PANSS. 
The healthy control subjects were randomly recruited from the same catchment area as 
the patients, were born in Norway and between 18 and 60 years old. All healthy controls 
underwent an initial interview where demographic and clinical information was obtained. 
Exclusion criteria were head injury, mental retardation, neurological disorder, a history of 
medical problems potentially interfering with brain function and illegal drug use. 
Additionally, control subjects were screened with the Primary Care Evaluation of Mental 
Disorders (Spitzer et al., 1994), and excluded if they or any close relatives had a lifetime 
history of a severe psychiatric disorder (SZ, BD, MDD). 
The Norwegian BRAIN sample 
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
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The Bipolar Research and Innovation Network (BRAIN) study is a Norwegian collaborative 
study including patients with BD from throughout Norway. To be eligible for the study, 
patients have to be above 18 years old and fulfill the criteria for BD I, BD II, or BD NOS 
disorder according to the DSM-IV criteria. Diagnoses were assessed with the SCID-1 for the 
DSM-IV (Spitzer et al., 1992) or the Mini-International Neuropsychiatric Interview (MINI-
Plus Version 4.4) (Sheehan et al., 1998). The patients were diagnosed by trained psychiatrists 
who held regular meetings to increase their inter-rater diagnostic reliability. By June 2009, the 
BRAIN study comprised a total of 252 patients (Schoeyen et al., 2011). 
The Danish sample 
The Danish patients were recruited from all over Denmark, and were diagnosed with either 
ICD-10 clinical assessment, Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
(Wing et al., 1990) interview fulfilling a best estimate diagnosis according to ICD-10-DCR or 
DSM-IV, or with the Operational Criteria Checklist for Psychotic Illness and Affective Illness 
(OPCRIT) semi-structured interview (McGuffin et al., 1991). The studies included in this 
thesis comprised Danish patients diagnosed with bipolar affective disorder F31, manic 
episode, F30, schizophrenia F20, schizotypal personality disorder F21, persistent delusional 
disorder F22 and schizoaffective disorder F25 according to ICD-10, bipolar I disorder 
according to DSM-IV, and bipolar disorder, mania with psychosis and bipolar with psychosis 
according to the OPCRIT classification system. 
The Danish control subjects were either recruited randomly from 15000 individuals 
from the Danish Blood Donor Corps in the Copenhagen area, or selected and screened for 
psychiatric disease for inclusion in a previous study (Mellerup et al., 2001). 
The Swedish sample 
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The Swedish patients were selected from psychiatric hospitals in the Stockholm area, and 
were diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, 
according to DSM-III-R/DSM-IV criteria using medical record reviews and clinical 
interviews. 
The Swedish control subjects were either selected from a group of individuals who 
had participated in previous biological psychiatric research at the Karolinska Institute or 
recruited from a population register in the Stockholm area. All the controls were of Caucasian 
origin (86 % Swedish, 6 % Finnish, 8 % European) and none suffered from schizophrenia.
5.1.2 Replication samples 
Icelandic bipolar disorder and schizophrenia case–control samples 
Patients and controls were recruited from all over Iceland. 316 of the BD patients were 
diagnoses according to Research Diagnostic Criteria (RDC) (Spitzer et al., 1978) using the 
Schedule for Affective Disorders and Schizophrenia Lifetime Version (SADS-L) (Spitzer, 
1977). The remaining BD patients were recruited through a genetic study of anxiety and 
depression (Thorgeirsson et al., 2003) and had been diagnostically assessed with the 
Composite International Diagnostic Interview (CIDI) (Peters and Andrews, 1995;Wittchen et 
al., 1996). The Icelandic SZ patients were diagnosed in accordance with the Research 
Diagnostic Criteria (RDC) (Spitzer, Endicott, and Robins, 1978) using the SADS-L (Spitzer, 
1977). The 11491 control subjects were recruited as a part of various genetic programs at 
deCODE genetics and were not tested for psychiatric disorders. 
WTCCC bipolar disorder case–control sample 
The Wellcome Trust Case Control Consortium (WTCCC) BD sample consisted of 1868 cases 
and 2938 controls, all from a British population. The patients were diagnosed with bipolar I 
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disorder, schizoaffective disorder bipolar type, bipolar II disorder or manic disorder according 
to Research Diagnostic Criteria (Spitzer et al., 1978) (WTCCC 2007). 
STEP-UCL/ED-DUB-STEP2 bipolar disorder case–control sample 
The STEP-UCL/ED-DUB-STEP2 BD sample (N = 2558 cases and 3274 controls of European 
descent) consisted of the STEP-UCL BD sample (N = 1460/2007) and the ED-DUB-STEP2 
BD sample (N = 1098/1267), and is described in details elsewhere (Ferreira et al., 2008;Sklar 
et al., 2008).
The studies in this dissertation used information from the following samples: 
SCOPE bipolar disorder and schizophrenia case-control samples: 
Study I: 594 BD cases and 1421 healthy controls 
Study II: 686 BD cases, 781 SZ cases and 2839 healthy controls 
Study III: 854 BD cases, 1073 SZ cases and 2919 healthy controls 
Study IV: 66 BD cases, 61 SZ cases and 123 healthy controls 
Replication samples: 
Icelandic bipolar disorder and schizophrenia case–control samples: 
Study II: 435 BD cases and 11491 controls 
Study III: 435 BD cases, 651 SZ cases and 11491 controls 
WTCCC bipolar disorder case–control sample: 
Study II: 1868 BD cases and 2938 controls 
STEP-UCL/ED-DUB-STEP2 bipolar disorder case–control sample:  
Study II: 2558 BD cases and 3274 controls 
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5.2 The genes studied 
DGKH 
Diacylglycerol kinase eta (DGKH) was selected on the basis on a prior finding from a GWAS 
reporting strong association between three SNPs in this gene and BD (Baum et al., 2008). 
DGKH is located on chromosome 13 and is encoding DGKH, a member of the diacylglycerol 
enzyme family. DGKH is involved in regulating the intracellular concentrations of 
diacylglycerol and phosphatidic acid, and has been shown to be a key protein in the lithium-
sensitive phosphatidyl inositol pathway (Berridge, 1989). Based on this, it has been 
hypothesized that DGKH plays a role in lithium response and affect regulation, an assumption 
that still awaits verification (Zeng et al., 2010).
PALB2 
PALB2 (partner and localizer of BRCA2) was selected due to the evidence of strong 
association between a PALB2 SNP and BD reported from a GWAS from 2007 (WTCCC 
2007). PALB2 is located on chromosome 16 and encodes for PALB2, a protein which binds to 
and co-localizes with BRCA2 (breast cancer 2, early onset) in the cell nucleus and promotes 
its stable localization in cellular structures like chromatin and nuclear matrix (Xia et al., 
2006). Mutations in PALB2 have been found to increase the risk for breast cancer (Rahman et 
al., 2007). 
BRCA2 
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BRCA2 was selected because of its function, which is closely related to that of PALB2. 
BRCA2 is located on chromosome 13 and encodes for BRCA2, a protein involved in DNA 
repair. A dysfunction in BRCA2 leads to an increased risk of developing certain forms of 
cancer, like breast cancer, as well as Fanconi’s anaemia (Tutt and Ashworth, 2002). 
Furthermore, and of particular relevance for our study, a recent report found BRCA2 to be of 
importance for normal neurogenesis in mice (Frappart et al., 2007). 
ANK3 
Anyrin3 (ANK3) was investigated on the basis of several GWA and candidate gene studies 
finding significant association between SNPs in ANK3 and BD (Ferreira et al., 2008;Lee et 
al., 2010;Schulze et al., 2009;Scott et al., 2009;Smith et al., 2009;Takata et al., 2011). ANK3 
is located on chromosome 10 and is expressed in the central and peripheral nervous system. 
Its encoded protein Ankyrin G has been shown to link membrane proteins to the cytoskeleton, 
and to be involved in the clustering of potassium channels and voltage-gated sodium channels 
at initial segments of the axon and for action potential firing (Kordeli et al., 1995;Pan et al., 
2006;Zhou et al., 1998). 
CACNA1C 
L-type voltage-gated calcium channel gene (CACNA1C) has also been found to be associated 
with BD in several association studies (Ferreira et al., 2008;Sklar et al., 2008). CACNA1C is 
located on chromosome 12 and encodes an alpha-1 subunit of a voltage-dependent calcium 
(Cav1.2) channel. These channels have a variety of functions, including excitation-contraction 
coupling, endocrine secretion and regulation of neuronal Ca2+ transients, enzyme activity and 
transcription. Mutations in CACNA1C have been shown to give rise to Timothy Syndrome, a 
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lethal condition consisting of symptoms like cardiac arrhythmia, autism and mental 
retardation (Splawski et al., 2004). 
5.3 Genotyping technologies 
GoldenGate® Assay 
GoldenGate 1536plex assay (Illumina Inc., San Diego, California, USA) uses a discriminatory 
DNA polymerase and ligase to investigate 1536 tagSNPs simultaneously. 36 tagSNPs in 
DGKH and 10 tagSNPs in BRCA2 were genotyped using the GoldenGate 1536plex assay on 
Illumina BeadStation 500GX at the SNP Technology Platform, Uppsala University, Sweden 
(www.genotyping.se), approved according to a quality system based on the international SS-
EN ISO/IEC 17025 standard and accredited by the Swedish accreditation agency SWEDAC.  
TaqMan®SNP Genotyping Assay 
The TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA) technology 
makes uses of a hydrolysis probe which binds to a target site on the genome. This probe is 
cleaved by the 5' exonuclease activity of the enzyme Taq Polymerase, resulting in an increase 
in fluorescence intensity. One SNP in DGKH, one PALB2 SNP, one BRCA2 SNP and two
ANK3 SNPs were genotyped with single-plex TaqMan SNP Genotyping Assay, at the 
Department of Medical Genetics Oslo University Hospital. 
Affymetrix Genome-Wide Human SNP Array 6.0 
Affymetrix Genome-Wide Human SNP Array 6.0 is a DNA microarray technology which 
enables the detection of 906600 SNPs on the entire genome simultaneously. In contrast to the 
Illumina chip, the Affymetrix chip is not based entirely on LD structure and tagSNPs. For a 
subset of the Norwegian sample, genotype data for one ANK3 SNP and one CACNA1C SNP 
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was extracted from a Norwegian GWAS data set comprising patients with BD and SZ, as well 
as healthy controls (Athanasiu et al., 2010;Djurovic et al., 2010). Individuals in this GWAS 
study were genotyped with Affymetrix Genome-Wide Human SNP Array 6.0 at Department 
of Medical Genetics Oslo University Hospital. 
5.4 fMRI analyses 
A negative faces matching paradigm was used to measure amygdala reactivity in the subjects 
included in study IV (Hariri et al., 2002). In this paradigm, the participants selected which of 
two stimuli (either human faces expressing anger or fear, or geometrical shapes) matched a 
target stimulus. The subjects completed 4 blocks of the faces matching task, where each block 
consisted of 6 emotion-specific face trios from a standard set of facial affect pictures 
(Tottenham et al., 2009). Between these 6 blocks, participants completed 5 blocks of 
matching geometrical shapes (sensorimotor control task). E-prime software (version 1.0 
Psychology Software Tools, Inc, Pittsburgh, PA, USA) controlled the presentations of the 
stimuli using VisualSystem (NordicNeuroLab, Bergen, Norway). Responses were made using 
ResponseGrips (NordicNeuroLab, Bergen, Norway). 
MRI scans were acquired on a 1.5 T Siemens Magnetom Sonata scanner (Siemens 
Medical Solutions, Erlangen, Germany) supplied with a standard head coil. 
fMRI volumes were preprocessed and analyzed with Statistical Parametric Mapping 
(SPM2) (http://www.fil.ion.ucl.ac.uk/spm) implemented in MATLAB7.1 (The Mathworks 
Inc, Natick, Massachusetts). Individual contrast images were created by subtracting “figures” 
from “faces”. Contrast images for each subject were entered into a random effects statistical 
model. These data were analyzed with a region of interest (ROI) approach and a pre-defined 
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anatomical mask (bilateral amygdala) derived from the Wake Forest University PickAtlas for 
SPM2 (Maldjian et al., 2003). 
5.5 Statistics 
All SNPs investigated in study I-III in this dissertation were tested for deviation from Hardy-
Weinberg equilibrium (HWE) in the controls. In the second and third study, we used the exact 
X2 test implemented in PLINK (version1.07;http://pngu.mgh.harvard.edu/purcell/plink), 
whilst in the first study we used the exact test implemented in the genetics package in R 
(www.r-project.org). 
In the first study, genotype-based association tests were calculated by the MAX-test 
(Freidlin et al., 2002), a test using the maximal test statistic for the recessive, dominant, and 
additive inheritance pattern implemented by different weights in the Cochrane–Armitage 
trend test. For each SNP, 10000 permutations were made to evaluate the underlying null 
distribution, and thus leading to corresponding P values. As a previous report found no 
indication of ethnic admixture in the controls included in the SCOPE samples (estimated 
overall gene-based fixation index (FST) = 0.00071) (Kähler et al., 2008), we did not correct 
for potential population stratification in this study. 
In the second and third study, allele tests were undertaken in each subsample, in 
addition to genotypic, trend, dominant and recessive models in the second study as 
implemented in the function “Model” in PLINK. In the SCOPE sample, Cochran–Mantel–
Haenszel (CMH) tests were performed in the second and third study, using case-control 
sample origin as the stratification factor. The heterogeneity of the sample specific odds ratios 
(ORs) was evaluated with the Breslow–Day test. For the total combined samples in the second 
study, the P value was assessed with Fisher`s combined probability test. The meta-analysis 
function in PLINK was used for the meta-analysis in the third study. Pairwise SNP_SNP 
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interaction analysis (PLINK) was performed for the two most significant SNPs in the second 
study. 
 Multiple testing correction in study I was performed with the Sidak approach, where 
the effective number of statistical tests was estimated by the Moskvina approach (Moskvina 
and Schmidt, 2008). This approach takes into consideration the dependency between the loci 
(i.e. the corresponding test statistics). In study II, gene-wise Bonferroni correction was used 
for the ten BRCA SNPs, and in study III we made use of Bonferroni correction for the three 
ANK3 SNPs. 
The statistical software used in study I-III in this dissertation were the genetics package 
in R (www.r-project.org) in study I and PLINK 
(version1.07;http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007) in study II and 
III. 
 The analyses in the fourth study were performed with the software program Statistical 
Parametric Mapping (SPM2) (http://www.fil.ion.ucl.ac.uk/spm) implemented in MATLAB7.1 
(The Mathworks Inc, Natick, Massachusetts). As multiple testing correction we applied 
Family-Wise Error (FWE) within the respective region of interest (ROI). 
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6 SUMMARY OF RESULTS 
Study I 
No association between DGKH and bipolar disorder in a Scandinavian case-control sample  
37 DGKH SNPs were genotyped in 594 BD cases and 1421 healthy controls of Danish and 
Norwegian origin. We found no significant association between these SNPs and BD after 
multiple-testing correction. Specifically, we found no significant association between the SNP 
rs1012053 previously identified in a GWA study and BD (Nominal P = 0.76). 
 These findings make it less likely that DGKH variants are involved in BD 
pathophysiology. 
Study II 
Association analysis of PALB2 and BRCA2 in bipolar disorder and schizophrenia in a 
Scandinavian case-control sample 
The PALB2 SNP rs420259 was genotyped in a sample of 686 BD cases, 781 SZ cases and 
2839 healthy controls. The ten BRCA2 tagSNPs were genotyped in a subsample of 554 BD 
cases and 1419 healthy controls, of which the most significant SNP (rs9567552) was 
genotyped in the remaining subjects of the total Scandinavian case-control sample. The 
BRCA2 SNP rs9567552 attained a nominal P-value of 0.00043 and the PALB2 SNP rs420259 
a nominal P-value of 0.025. When we combined the latter result with results from an Icelandic 
BD case-control sample (N = 435 BD cases and 11491 controls), the WTCCC BD sample (N 
= 1868 BD cases and 2938 controls) and the STEP-UCL/ED-DUB-STEP2 study (N = 2558 
BD cases and 3274 controls) in a meta-analysis, we calculated a P-value of 1.2 x 10-5 for 
association between PALB2 SNP rs420259 and BD (N = 5547 BD and 20241 controls). None 
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of the SNPs were nominally significantly associated with SZ in our Scandinavian sample (N = 
781 SZ cases and 2839 healthy controls). 
These findings suggest that genetic variants in PALB2 and BRCA2 may increase the 
risk of developing symptoms which are more prevalent in the BD spectrum than in the SZ 
spectrum of the proposed continuum of severe psychiatric disorders. Furthermore, it opens the 
possibility for altered DNA repair related to neurogenesis in BD pathophysiology. 
Study III 
Association analysis of ANK3 gene variants in Nordic bipolar disorder and schizophrenia 
case-control samples 
We genotyped the three ANK3 SNPs rs10994336, rs1938526 and rs9804190 in a 
Scandinavian case-control sample (N = 854 BD cases, 1073 SZ cases and 2919 healthy 
controls). When adding the results from this sample to the results from an Icelandic case-
control sample (N = 435 BD cases, 651 SZ cases and 11491 controls), we found rs10994336 
and rs9804190 to be nominally significantly associated with BD. Nominal P was 0.015/0.018 
(fixed/random effect) for rs10994336 (Bonferroni corrected P = 0.044/0.053) and 0.023 for 
rs9804190 (Bonferroni corrected P = 0.069) in this combined Nordic sample (N = 1289 BD 
cases and 14105 controls). None of the SNPs were significantly associated with SZ. 
Our findings suggest allelic heterogeneity for ANK3 in BD and ion channelopathy as a 
potential underlying neurobiological mechanism. 
Study IV 
CACNA1C risk variant and amygdala activity in bipolar disorder, schizophrenia and healthy 
controls 
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We investigated if carriers of a CACNA1C risk allele had altered amygdala activation during a 
negative faces matching paradigm in a sample of 66 BD cases, 61 SZ cases and 123 healthy 
controls, all of Norwegian origin. In the total sample (N = 250), we found enhanced activity 
in the left amygdala in risk allele carriers (x = -24, y = -2, z = -14; Z = 3.47) (FWE P = 
0.026). There was also a significant association for increased activity in the left amygdala in 
the BD group (x = -24, y = 0, z = -14; Z = 3.35) (FWE P = 0.041), but not in the SZ or healthy 
control group when analyzing group wise. 
The current findings strengthen the hypotheses of CACNA1C involvement in BD and 
ion channelopathy and increased amygdala activity as pathophysiological mechanisms. 
Overall summary 
In all the studies in this thesis we investigated genetic variants which were strongly associated 
with BD in previous GWA studies. Of these variants, we replicated the association between a 
PALB2 SNP and BD and detected a novel association between BRCA2 and BD, found 
borderline significant association between two ANK3 SNPs and BD, and no association 
between a DGKH SNP and BD in our Nordic BD sample. In our fourth study, we found 
carriers of a CACNA1C risk allele to have increased amygdala activity, most pronounced in 
the BD subgroup. 
Taken together, these findings make it more likely that genetic variants in PALB2 and 
ANK3 increase the risk of developing BD, while it decreases the probability that DGKH is 
related to the disorder. Furthermore, in strengthens the hypothesis that ion channelopathy is 
involved in BD pathophysiology, as both ANK3 and CACNA1C have functions related to ion 
channel regulation, and that amygdala over-activation may be an underlying mechanism for 
BD.
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7 DISCUSSION 
7.1 Discussion of results 
The main findings in the studies in this thesis were significant associations between genetic 
variants in PALB2, BRCA2, ANK3 and BD, no association between DGKH and BD, and 
amygdala over-activation in carriers of a CACNA1C risk allele, most pronounced in BD. 
 Since the studies in this thesis were planned and undertaken, the afore-mentioned 
international multicenter PGC study was published, comprising 11974 BD cases and 51792 
controls (Ripke et al., 2011;Sklar et al., 2011). As this is the largest case-control association 
study in psychiatric genetics, with more statistical power than previous studies, the results in 
this thesis must be interpreted in the perspective from the PGC mega-analysis, as well as from 
other major studies. 
 In the first article in this dissertation, we found no association between SNPs in 
DGKH and BD. The SNP formerly found associated with BD (rs1012053) (Baum et al., 
2008), obtained a P-value of 0.70 in our study, with OR in opposite direction. Two other 
studies have reported negative findings for DGKH SNPs and BD (Ollila et al., 2009;Yosifova 
et al., 2009), whereas one Sardinian study (Squassina et al., 2009) and one Chinese study 
(Zeng et al., 2011) found association between DGKH haplotype blocks and BD. In the PGC 
BD mega-analysis, the P-value for rs1012053 was 0.0087 (p = 0.26 for SZ, but OR in 
opposite direction) (Sklar et al., 2011). Taken together, there are inconclusive results for 
DGKH SNPs and BD, but considering the low statistical power for some of these studies and 
the biological rationale, this is nevertheless a gene which warrants further investigation in BD. 
 In study II, PALB2 SNP rs420259 was associated with BD in the meta-analysis (N = 
5547/20241), with a nominal P-value of 1.2 x 10-5, but not with SZ. Our meta-analysis 
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included the WTCCC sample, where the primary association between this PALB2 SNP and 
BD was detected (WTCCC 2007). A Finnish family-based BD association study (N = 723) 
(Ollila et al., 2009) found no association for this SNP, but the statistical power of this study 
was smaller than in our study and the WTCCC study. Further, our results for PALB2 are in 
line with corresponding P-values from the PGC study is (P = 0.006 for BD and 0.052 for SZ; 
ORs in the same direction as in our study) (Sklar et al., 2011), and indicates that this SNP 
might increase the risk of developing BD, but not SZ to the same degree. Nonetheless, this 
SNP did not reach genome-wide significance in the PGC BD sample, and the OR was lower 
than in our study (1.07 vs 1.19 for risk allele A). This might indicate that the true effect size is 
lower than first reported (winner’s curse), or that carriers of the risk allele constitute a 
subgroup of BD patients. As for our association between BRCA2 SNP rs9567552 and BD, 
(Nominal P = 0.00043) in the Scandinavian sample (N = 686 BD cases and 2839 healthy 
controls), the corresponding P-value in the PGC study was 0.11 with OR in the opposite 
direction, and there are no available results for the SZ sample. To best of our knowledge, no 
other studies have investigated this genetic variant in psychiatric disorders. Thus, in the 
perspective of the present findings, it is less likely that this SNP confers susceptibility to BD, 
at least not to the entire BD phenotype and in all populations. 
The two ANK3 SNPs rs10994336 and rs9804190 were nominally significantly 
associated with BD in our combined Nordic sample (N = 854 BD cases and 2919 healthy 
controls), but only borderline significantly associated after correcting for multiple testing. 
These results are in line with previous findings on ANK3 and BD, with regards to statistical 
power and effect size. Since the primary evidence of association between ANK3 SNPs and BD 
(Ferreira et al., 2008), several studies have found rs10994336 (Schulze et al., 2009;Scott et al., 
2009), rs9804190 (Schulze et al., 2009) and rs1938526 (Lee et al., 2011;Smith et al., 
2009;Takata et al., 2011) to be associated with BD. One study found another ANK3
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SNP (rs10761482) to be associated with SZ (Athanasiu et al., 2010). Results from the PGC 
study support these findings (P = 7.96 x 10-6 for rs9804190 in the BD sample and 0.065 in the 
SZ sample; both ORs in the same direction as in our sample; no results available for 
rs10994336 and rs1938526). On this basis, ANK3 is one of the most consistent findings 
among the proposed risk genes for BD. Moreover, the ANK3 variants studied in this thesis do 
not seem to increase the risk for SZ to the same degree as for BD. 
 As for CACNA1C, several reports have found rs1006737 to be associated with BD 
(Ferreira et al., 2008;Sklar et al., 2008), SZ (Green et al., 2010;Nyegaard et al., 2010) and 
MDD (Green et al., 2010). In the PGC study, the same allele was associated with both BD (P 
= 1.73 x 10-5) and SZ (P = 1.17 x 10-6). Thus, there is robust evidence for overlap at the 
clinical phenotype level for this genetic variant. With regards to brain activity, two fMRI 
studies reported enhanced amygdala activity for carriers of the rs1006737 risk allele (Jogia et 
al., 2011;Wessa et al., 2010), but neither of these studies determined the potential diagnostic 
specificity of this association. In study IV in this thesis, having the CACNA1C risk allele, was 
associated with significantly enhanced activity in the left amygdala in the total sample (N = 
250), and in the BD group (N = 66), but not in the SZ or healthy control group when 
analyzing the groups separately. This suggests that the currently studied risk allele has an 
effect on amygdala activation in all individuals, which is more pronounced in BD subjects. 
7.1.1 PALB2, BRCA2, DNA repair and neurogenesis 
In study II, we replicated the association between the PALB2 SNP rs420259 and BD, which 
was previously reported in a GWA study from 2007 (WTCCC 2007). Additionally, we found 
a novel association between BRCA2 SNP rs9567552 and BD. The lack of significant 
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associations between these two SNPs and SZ indicates no genetic overlap between BD and 
SZ for these SNPs. 
The encoded proteins from BRCA2 and PALB2 are functionally related in DNA repair 
mechanism, and variants in both genes have been shown to increase the risk for developing 
breast cancer and other forms of cancer (Rahman et al., 2007; Tutt and Ashworth, 2002). A 
recent study showed that BRCA2 is important for normal neurogenesis in mice, particularly in 
the cerebellum (Frappart et al., 2007). There is evidence for cerebellar involvement in 
emotional processing, and reduced cerebellar volume and activity has been observed in BD 
(Bolbecker et al., 2009;Konarski et al., 2005). Further support comes from a Diffusion 
Tension Imaging study finding reduced cerebellar gray matter density in pediatric BD (James 
et al., 2011). On this basis, it seems possible that genetic variants in BRCA2, and the 
functionally related gene PALB2, may modulate the neurogenesis in certain brain regions, like 
the cerebellum, whose activity in turn might give rise to emotional dysregulation, manifesting 
as mania or depression. 
 With regards to the relationship between severe psychiatric disorders and cancer, it has 
been hypothesized that individuals suffering from SZ have lower incidence rates of cancer 
than healthy individuals. A meta-analysis comprising studies of cancer incidence in SZ cases 
and their first-degree relatives compared with general population samples, reported that the 
overall cancer incidence in SZ patients was not significantly increased. They found slightly 
increased lung cancer incidence, which was reduced after adjusting for smoking prevalence, 
whereas the incidence of other forms of cancer unrelated to smoking was reduced in SZ 
patients. Breast cancer was more prevalent in female patients, and the total cancer incidence 
in relatives was significantly reduced (Catts et al., 2008). As for BD, fewer studies on cancer 
incidence are published, but of the few reports available, one reported significantly enhanced 
cancer risk in BD subjects in both genders, and a trend-significantly increased risk for breast 
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cancer in females (Barchana et al., 2008). Several possible explanations of these relations 
have been proposed; one suggests that neuroleptics have a protective effect against cancer in 
SZ patients (Mortensen, 1994), another indicates that the increased prolactin level resulting 
from neuroleptics increases the risk of breast cancer (Grinshpoon et al., 2005), and a third 
hypothesis proposes that the relation between severe psychiatric disorders and cancer may 
result from the underlying genetic variation (Catts and Catts, 2000). 
 From this perspective, it was interesting to explore how our PALB2 and BRCA2 
candidate risk variants for BD might relate to breast cancer. The BRCA2 SNP rs9567552 has, 
to our knowledge, not been studied in breast cancer, but the PALB2 SNP rs420259 
investigated in our study, is in LD (r2 = 1.0 based on the Chinese HapMap population; r2 = 
0.84 in CEU), with the PALB2 SNP rs249954, which was found to be associated with breast 
cancer (G/A, A risk allele) in a Chinese study (Chen et al., 2008). The G allele of rs249954 is 
in LD with A of rs420259, according to www.hapmap.org. Hence, the risk allele for breast 
cancer is in LD with the protective allele for BD. There are several ways to interpret this 
phenomenon, taking into consideration that we do not know which SNP is causatively 
associated with these two diseases. One possible explanation is that the same SNP is 
protective for one phenotype and confers risk to the other, in which case the increased 
incidence of breast cancer in BD could be independent of these SNPs. Another interpretation 
is allelic heterogeneity at the same locus in different populations, which could imply that the 
risk allele for BD/breast cancer in Europeans is the protective allele in the Chinese population 
and vice versa (Hennah et al., 2009). A third possibility is false positive findings, which might 
very well be the case with BRCA2, in the light of the recent PGC findings. 
BRCA2 and PALB2 variants have been shown to increase the risk for developing 
breast cancer, ovarian cancer and other cancer types (Rahman et al., 2007;Tutt and Ashworth, 
2002;Wooster et al., 1995). In this respect, it is important to mention that the SNPs selected 
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for study II in this thesis were chosen on the basis of one previous report on BD (PALB2) 
(WTCCC 2007), and on tagSNPs from the Goldengate assay (BRCA2), without any prior 
knowledge on how these variants might relate to cancer incidence. Furthermore, the known 
genetic risk variants for breast and ovarian cancer are most often rare deleterious mutations, 
and not common SNPs (Pylkas et al., 2008). A recent review article concluded that with the 
current knowledge on breast cancer risk genes, we lack evidence for justification of screening 
for common low penetrance genetic variants (Ripperger et al., 2009). Hence, it is unlikely that 
the SNPs genotyped in our study could have any significant predictive value for diagnostic 
assessment of cancer. 
7.1.2 Ion channelopathy in bipolar disorder  
Several GWA and candidate gene association studies have found association between SNPs in 
CACNA1C and ANK3 and BD (Ferreira et al., 2008;Schulze et al., 2009;Sklar et al., 2011). 
Study III in this thesis adds evidence on diagnosis level to these findings, while study IV 
explores further a potential underlying neurobiological mechanism. 
 Interestingly, both CACNA1C and ANK3 encode for proteins known to be involved in 
ion channel regulation. CACNA1C encodes for an alpha-1 subunit of a voltage-dependent 
calcium (Cav1.2) channel, and ANK3`s encoded protein Ankyrin G has been shown to be 
important for clustering of potassium channels and voltage-gated sodium channels at axon 
initial segments (Jenkins and Bennett, 2001). Based on these findings, it has been 
hypothesized that ion channelopathy may be an etiological factor in BD. 
Channelopathies are mutations that change the function of ion channels in such a way 
that they give rise to clinical syndromes, including cardiac arrhythmias and neurological 
disorders like ataxia, epilepsy, migraine and headache (Kullmann, 2010). Until recently, there 
has been little evidence for implication in psychiatric disorders, and the associations found 
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between ANK3 and CACNA1C and BD shed new light on this tentative pathophysiological 
mechanism. CACNA1C mutations have been found to lead to Timothy syndrome, a rare and 
lethal disorder consisting of somatic symptoms like cardiac arrhythmia, dysmorphic facial 
features, syndactyly digits, dysregulation of the immune and secretory systems, and 
psychiatric symptoms like autism and cognitive disability (Splawski et al., 2004). In patients 
with Timothy syndrome mutations, there is an impaired Cav1.2 channel inactivation, and a 
sustained influx of calcium into the myocytes during action potential, resulting in longer QT 
intervals (Bidaud and Lory, 2011). Alas, Timothy syndrome mutations lead to a gain of 
function of Cav1.2 channels, whereas in another inherited calcium channelopathy syndrome, 
the Brugada syndrome, mutations result in a loss of function of Cav1.2 (Bidaud and Lory, 
2011).  A recent study on Timothy syndrome investigated cortical neuronal precursor cells 
and neurons from induced pluripotent stem cells in subjects with Timothy syndrome. The 
authors reported that these cells had defective calcium signaling and activity-dependent gene 
expression. Further, these neurons displayed abnormal differentiation, abnormal expression of 
tyrosine hydroxylase and increased production of norepinephrine and dopamine. Intriguingly, 
these features proved to be reversed by roscovitine, a cyclin-dependent kinase inhibitor and 
atypical L-type-channel blocker (Pasca et al., 2011). 
To the best of our knowledge, the effect of the risk allele A in the CACNA1C SNP 
rs1006737 on its expressed protein is not known. But as rs1006737 is situated in one of the 
introns of CACNA1C, it is probably regulating the expression of the protein rather than 
changing its structure, as is the case with Timothy syndrome, in which the causative de novo 
mutations are located in one of the exons (Splawski et al., 2005). If we consider a sliding-
scale model of a spectrum of psychiatric disorders, with autism in the neurodevelopmental 
end and MDD in the affective end (Craddock and Owen, 2010), we could speculate that 
polymorphisms regulating the expression of the CACNA1C gene might confer risk to less 
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severe conditions (like BD and SZ) than those observed resulting from Timothy syndrome 
mutations. Further, this spectrum might not be confined to psychiatric disorders. It is possible 
that channelopathies predispose to a broad group of neuropsychiatric disorders, including 
epilepsy, migraine, ataxia, autism, SZ, BD and MDD. Interestingly, some neurological 
disorders caused by channelopathies (epilepsy, migraine, dyskinesia) are paroxystic in nature, 
like BD (Ryan and Ptacek, 2010). Moreover, the PGC study found the CACNA1C SNP 
rs1006737 to be associated with both BD (P =1.7 x 10-5; OR = 1.11) and SZ (P = 1.2 x 10-6; 
OR = 1.11) (Ripke et al., 2011), at similar significance levels and with the same effect sizes. 
Hence, the different clinical manifestations could be conditioned by different gene-gene 
interactions, epigenetic factors and gene-environment interactions. In line with this proposed 
model, the findings from our fourth study suggest that this CACNA1C risk allele increases 
amygdala activity in all individuals, but with a more prominent effect in BD subjects, possibly 
due to other genetic and environmental risk factors. 
With regards to the pharmacological implications of the association between 
CACNA1C and BD, the calcium channel blocker Verapamil has been shown to have an effect 
on cardiac arrhythmia in Timothy syndrome (Bidaud and Lory, 2011). Calcium channel 
blockers have also been studied in mood and substance abuse disorders (Casamassima et al., 
2010). Some promising early results have been reported for dihydropyridine-based blockers 
that bind specifically to Cav1.2 channels in the treatment of BD, but larger studies are needed 
(Keers et al., 2009). The above-mentioned drug roscovitine should also be taken into 
consideration for further investigation (Pasca et al., 2011). However, as long as the effect of 
the CACNA1C BD risk variants on protein structure and expression level remains unknown, it 
will be difficult to develop specific pharmacological treatments based on the channelopathy 
theory. 

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As for ANK3 and the channelopathy hypothesis for severe psychiatric disorders, recent 
studies have yielded interesting results. One animal study showed that axons of ankyrinG-
deficient mice develop resembling features with dendrites, and that ankyrinG therefore is 
important for maintaining appropriate axo-dendritic polarity in vivo (Sobotzik et al., 2009). 
This finding is in accordance with a cell study reporting that silencing of the expression of 
ankyrinG dismantles the axonal initial segment and gives axons similar characteristics as 
dendrites (Hedstrom et al., 2008). As the effect of the ANK3 polymorphisms associated with 
BD on the expressed protein is still unknown, two recent studies are of interest in this respect. 
An animal study found ANK3 and calcium channel subunits to be downregulated in the mouse 
brain in response to lithium (McQuillin et al., 2007). As lithium is a potent mood-stabilizing 
drug, this finding might be interpreted as an evidence for increased expression of ankyrinG in 
BD cases. This seems slightly contradictory to the findings from a recent translational study, 
in which ANK3 mRNA expression levels were lower in SZ subjects than in healthy controls 
and ANK3 expression was lower in carriers of the ANK3 SNP rs9804190 C allele (Roussos et 
al., 2012). However, the pathophysiological mechanisms by which ANK3 SNPs are related to 
BD and SZ might differ, mRNA expression levels could vary from one brain region to 
another, and the effect of lithium on BD might be unrelated to the impact of ANK3 risk 
alleles. 
To summarize, it remains unclear whether the polymorphisms in CACNA1C and 
ANK3 found to be associated with BD result in hyper- or hypofunction of the expressed 
proteins. Future studies investigating mRNA levels and other potential endophenotypes could 
address this question and add to the growing body of knowledge on the putative role of 
channelopathies in BD. 
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7.1.3 Increased amygdala activity - an endophenotype for BD? 
In the fourth study in this thesis, we found increased activity in carriers of the CACNA1C SNP 
rs1006737 risk allele in the left amygdala in the overall sample, with a more pronounced 
effect in the BD subsample than in the SZ and healthy control subsamples. 
In order to assess whether increased amygdala activity is an endophenotype for BD, and to 
what extent our findings add to prior knowledge on this subject, we should go back to the 
criteria from the introductory section in this thesis, and see if they are fulfilled by the current 
findings. 
1. The endophenotype is associated with illness in the population. 
As stated in the introduction, a recent meta-analysis (N = 1040 BD cases and 1074 healthy 
controls) reported increased amygdala activity in BD subjects compared to healthy controls 
during emotional paradigms (Chen et al., 2011). However, the studies included in this meta-
analysis are rather small, and the findings are not entirely consistent from study to study. 
Larger studies with both emotional and cognitive paradigms are needed to address this 
question properly. 
2. The endophenotype is heritable. 
To the best of the author’s knowledge, no studies have explicitly investigated the heritability 
of amygdala activity or volume, neither in terms of epidemiology nor molecular genetics. But 
at least two imaging genetics studies have investigated the influence of genetic variants on 
amygdala activity. Both studies used the CACNA1C SNP rs1006737 as independent variable 
and amygdala activity as dependent variable. The first study found increased activation in the 
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right amygdala in a reward paradigm for healthy carriers of the risk allele (N = 64) (Wessa et 
al., 2010), whereas the latter found increased activation in the right amygdala in carriers of the 
risk allele during a fear-face paradigm (N = 41 euthymic BD cases, 25 relatives and 50 
healthy controls) (Jogia et al., 2011). 
 Our study is substantially larger than these studies, and comprises SZ cases in addition 
to BD cases and healthy controls. Our findings confirmed the association between this genetic 
variant and increased amygdala activity, and provided new evidence for a more pronounced 
effect in patients suffering from BD. 
 Based on these three studies, is seems like carriers of this CACNA1C SNP have an 
enhanced amygdala activation, but more studies are needed before concluding on diagnostic 
specificity for BD. It is also unclear whether the increased amygdala activation pattern is 
unilateral or bilateral. The two previous studies reported over-activation only in the right 
amygdala, whilst we found a stronger effect in the left amygdala. However, there were trend-
significant associations also in the right amygdala in our total sample (x = 26, y = 0, z = -16, 
Z = 2.65, cluster-size = 32) and in the BD subgroup (x = 22, y = 0, z = -20, Z = 2.54, cluster-
size = 61). This might indicate bilateral increased amygdala activation in AA/AG carriers, not 
reaching significance level due to low statistical power in these three studies. The above-
mentioned meta-analysis reported higher activation in the left medial temporal 
structures (parahippocampal gyrus, hippocampus and amygdala) in BD in six studies, and 
lower activation in similar regions in the right hemisphere in two studies (Chen et al., 2011). 
However, this discrepancy might result from different inclusion criteria, low statistical power 
and different paradigms. A potential problem when performing fMRI meta-analyses and 
replication studies is the various paradigms used by different research groups. We used a 
negative faces matching paradigm in our study, while the other studies used a fairly similar 
fear-face paradigm (Jogia et al., 2011) and a reward paradigm (Wessa et al., 2010). Although 
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all these paradigms have been validated for measuring amygdala activity, this activation 
might be the end-result of different mechanisms, like positive/ negative conditioning and 
relevance detection (Ousdal et al., 2008;Sander et al., 2003). 
 Further, the abnormal amygdala activation reported in BD cases could be a cause to as 
well as effect of pathological processes related to the disorder. However, the fact that a known 
risk genetic variant for BD is associated with increased amygdala activity in both healthy 
controls and BD cases, strengthens the hypothesis that increased amygdala activity is a 
genetically conditioned biological cause to the BD clinical phenotype. 
 With regards to the variation in amygdala activity explained by the CACNA1C risk 
SNP, it seems rather unlikely that a substantial part of this could be determined by one SNP, 
taken into consideration the polygeneity in BD and the low effect size for each single variant. 
On the other hand, as the genotypic variation probably lies closer to amygdala activity than to 
the clinical phenotype, the effect size for each variant may be larger and the polygeneity 
smaller at the brain activity level. To obtain more information on the heritability of amygdala 
activity, larger GWA studies and candidate gene studies should be performed, with well-
defined and validated paradigms. Findings from such studies should be compared with those 
from BD studies, to assess the genetic co-heritability. 
3. The endophenotype is primarily state-independent (manifests in an individual whether 
or not illness is active). 
In the afore-mentioned meta-analysis, increased amygdala activity was reported in euthymic 
BD cases compared to healthy controls (Chen et al., 2011). Thus, this suggested 
endophenotype seems to be state-independent. To further investigate this state/trait-
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relationship, one should compare euthymic subjects with individuals in manic/hypomanic and 
depressed state, in different emotional and cognitive paradigms, as well as in resting-state.  
4. Within families, endophenotype and illness co-segregate. 
One study (N = 20 BD I cases, 20 unaffected 1st degree relatives, 20 healthy controls) 
reported increased activation in the left amygdala in patients and relatives in response to 
intensively happy faces (Surguladze et al., 2010). But these findings need to be confirmed in 
larger studies and further investigated with other paradigms. 
  
Taken together, there is evidence for increased amygdala activity in euthymic BD 
cases compared to healthy controls, and one genetic variant in CACNA1C has been shown to 
increase the amygdala activity in the general population, possibly with a more prominent 
effect in BD. However, we still lack knowledge on the overall heritability of amygdala 
activity, the relationship between amygdala heritability and the heritability of BD, on familiar 
co-segregation of phenotype and potential endophenotype, and on the relation between state 
and trait activity. Moreover, the activation patterns between amygdala and other parts of the 
brain should also be investigated further in BD. 
7.1.4 Pleiotropic effects for bipolar disorder risk variants? 
In study II, III and IV in this thesis, we investigated genetic variants previously associated 
with BD, in patients diagnosed with SZ and BD. We did not find evidence for overlap at 
diagnosis level in study II and III, and the results from study IV indicated a general effect for 
the CACNA1C risk SNP independent of diagnostic category, with a possibly stronger effect in 
BD cases. 
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 In the introductory section of this thesis we outlined several hypothesized models 
describing the relationship between severe psychiatric disorders, hereunder the pre-
kraepelinian unitary psychosis model, the kraepelinian disctinction between manic depressive 
illness and dementia praecox, two or more overlapping categories and a floating continuum 
(figure 2) (Craddock et al., 2009). Of these models, the unitary psychosis model and the 
kraepelinian dichotomy could probably be rejected on the basis of recent studies. In the 
above-mentioned Swedish epidemiological study comprising 9 million subjects, first-degree 
relatives of BD cases were found to have 7.9 % risk for BD and 3.9 % risk for SZ 
(Lichtenstein et al., 2009). This is a clear evidence for a partial overlap between BD and SZ, 
excluding the unitary psychosis model as well as the dichotomous model. Recent molecular 
genetic studies have provided evidence for at least three common genetic risk variants for BD 
and SZ (CACNA1C, ANK3 and the ITIH3-ITIH4 region) (Ripke et al., 2011), but also genetic 
variants more specific to SZ than BD, like CNVs (Stefansson et al., 2008) and the extended 
major histocompatibility complex (MHC, 6p21.32-p22.1) (Ripke et al., 2011;Stefansson et al., 
2009). Additionally, one recent study reported a different polygenic score for SZ risk variants 
in subjects diagnosed with schizoaffective bipolar disorder (N = 277) than those with BD (N 
= 1552). However, they found no significant difference between psychotic and non-psychotic 
BD (Hamshere et al., 2011). This finding is in line with a recent subphenotype GWA analysis 
(N = 2836 BD cases and 2744 controls), in which no SNP obtained genome-wide significance 
level for age at onset or psychotic symptoms (Belmonte et al., 2011). 
The hypothesis of partial overlap between BD and SZ is further supported by imaging 
and neurocognitive studies. In a brain volumetric study, patients diagnosed with BD and SZ 
were found to have smaller subcortical volumes than healthy controls, and BD I and SZ cases 
had smaller volumes in prefrontal regions. For both findings, there was in general a more 
pronounced effect in SZ than BD (Rimol et al., 2010). On the neurocognitive level, there is 
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evidence for impairment in individuals with SZ as well as BD, and this impairment seems to 
be dependent on the number of psychotic episodes rather than on diagnostic category 
(Simonsen et al., 2011). Furthermore, neurocognitive dysfunction is found to be more severe 
in BD I than in BD II cases (Simonsen et al., 2008). 
In a recent article, the authors suggested a continuum model of severe psychiatric 
disorders with an inverse sliding gradient of affective and neurodevelopmental pathology, 
MDD in the affective end, moving on to BD, schizoaffective disorder, SZ, autism, and mental 
retardation in the neurodevelopmental end. In this model, there is overlapping heritability 
crossing the current diagnostic boundaries, with structural genetic variants more prevalent in 
the neurodevelopmental end and single genetic variants conferring risk to different parts of, or 
to the whole, diagnostic spectrum (Craddock and Owen, 2010). The authors suggest that it is 
time to leave the Kraepelinian categories, and create a new model, either with dimensions, 
multiple overlapping categories, or both, which lie closer to the underlying biological 
findings, and at the same time closer to the every-day clinical experience of inter-individual 
symptomatological heterogeneity. However, in order to create such a model and implement it 
in research and clinical practice, more studies on the molecular genetic level as well as on all 
possible endophenotype levels of severe psychiatric disorders are needed. 
7.2 Methodology – strengths and limitations 
7.2.1 GWAS versus candidate gene approach 
One of the major advantages of GWA studies is that they are hypothesis-free, i.e. the results 
from these studies are not biased by a priori hypotheses of the researchers. On the other hand, 
when investigating up to one million genetic variants, the risk of getting false positive 


findings before multiple testing correction as well as false negative findings after multiple 
testing correction is substantially increased compared to candidate gene studies. As for 
candidate gene studies, a major strength is the reduced need for multiple testing correction 
and the resulting reduced number of false negative findings. But the limited possibility for 
screening a vast number of variants across the entire genome makes this approach inefficient 
in the search for novel and unexpected risk variants, and dependent on the already existing 
hypotheses for potential risk genes. A general problem in psychiatric genetics, for both 
candidate gene and GWA studies, has been low statistical power, a phenomenon which until 
recently resulted in a lack of consistency between studies (Craddock et al., 2009;Porteous, 
2008). This phenomenon is most likely due to the polygenic nature of severe psychiatric 
disorders, and the low effect size of each single risk variant. However, the most recent 
multicenter GWA studies of BD (Ferreira et al., 2008;Sklar et al., 2011) have shown a larger 
degree of consistency, which implies that in order to obtain a level of adequate statistical 
power, several thousands of subjects are probably needed. Furthermore, to address the 
problem with false positive findings, it has shown to be important with replication of previous 
results in the field of psychiatric genetics. 
 The studies included in this thesis have used the advantage of highly significant 
findings from previous well-powered BD GWA studies (WTCCC 2007;Baum et al., 
2008;Ferreira et al., 2008). We have explored potential biological pathways for these variants, 
in order to test novel hypotheses, such as genetic overlap with SZ and increased amygdala 
activity as a BD endophenotype. One of the strengths of this approach is that the hypotheses 
are based on empirical evidence as well as on a biological rationale. One might say that this 
approach re-introduces the importance of candidate gene studies as a post-GWAS research 
method. One of the disadvantages with this approach is the reduced the possibility for 
discovering new genetic variants. 
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7.2.2 Materials - clinical phenotypes and population stratification  
One disadvantage with using psychiatric diagnostic categories like BD and SZ as phenotypes, 
is their symptomatological definitions. The lack of biomarkers in the diagnostic assessment 
for these disorders might give rise to heterogeneity at the phenotypic level, which could 
reduce the statistical power to detect risk variants. However, high heritability and cross-
heritability estimates for BD and SZ (Lichtenstein et al., 2009) imply common and partially 
shared underlying mechanisms for these disorders. 
 A further limitation in this regard is the different diagnostic assessment tools used in 
the studies in this thesis, as we have used DSM-IV for the Norwegian TOP sample and the 
Swedish sample, and ICD-10 and the OPCRIT system for the Danish sample. Additionally, 
cases included in the Icelandic replication sample were assessed with RDC and CIDI. But a 
Danish study from 2006 showed high diagnostic agreement of SZ across the ICD-10 and 
DSM systems (pairwise concordance rate (CR) > 0.70,  > 0.70) (Jakobsen et al., 2006). To 
correct for the potential phenotypic discrepancies between our samples, we applied the 
Cochrane-Mantel-Haenszel (CMH) method using “sample origin” as stratification factor in 
our statistical analyses in study II and III. Also, phenotypic heterogeneity would most likely 
increase the rate of type II errors, and not type I errors. In this regard, our studies are probably 
more susceptible to false negative than false positive findings. 
 The CMH method was also used for correcting for potential genetic differences across 
the Scandinavian samples in study II and III, and between the Scandinavian, Icelandic and 
British WTCCC samples in the meta-analysis in study II. Admixture of populations with 
different genetic architectures, if not corrected for, might lead to type I as well as type II 
errors. As for potential population stratification between our Scandinavian samples, a study 
from 2008 found no evidence for this (Kähler et al., 2008). Furthermore, a study of more than 
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2500 individuals from 23 European subpopulations, using Affymetrix GeneChip 500K 
genotype data, reported continent-wide correlation between geographic and genetic distance 
and little genetic differentiation between the subpopulations. Moreover, northern European 
populations showed less heterozygosity and smaller mean LD than southern European 
populations (Lao et al., 2008). 
7.2.3 Statistical power and multiple testing correction 
Statistical power is the probability that a test will reject a false null hypothesis, and is 
dependent upon several factors. The Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) uses the following criteria for determining the 
statistical power of a given case-control association study: 
• Risk allele frequency  
• Disease prevalence 
• Relative risk for homozygous and heterozygous carriers of the risk allele         
• LD between the investigated marker and the true risk allele  
• Number of cases                    
• Control/case ratio               
• Selected/unselected controls  
Statistical power is highest when the risk allele frequency equals 0.50, the D’ for LD between 
the investigated and true risk marker is 1 and the markers are equally frequent. Furthermore, 
statistical power increases with increasing number of cases and controls, if the controls are 
selected, and with an allelic statistical model. 
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 Of the studies included in this thesis, we performed statistical power analyses only in 
study III. We used the above-mentioned Genetic Power Calculator to calculate the power to 
detect P = 0.05 and number of cases needed for statistical power of 80%. We used a 10:1 
control/case ratio, and effect sizes were based on ORs for the respective SNPs reported in 
previous studies (Ferreira et al., 2008;Schulze et al., 2009). For the three ANK3 SNPs 
investigated (rs9804190, rs10994336 and rs1938526), the respective power estimates were 
0.9727, 0.9993 and 0.9985, and the numbers of cases needed for statistical power of 80% 
were 677, 386 and 420. The discrepancies were most likely due to differences in previously 
reported ORs, which were, respectively, 1.21, 1.45 and 1.395. However, these ORs might 
have been slightly inflated, as the corresponding OR for rs9804190 in the PGC study was 
1.17, and taken into consideration the fact that the first association between a marker and 
disease tend to report higher effect sizes than replication studies, a phenomenon termed 
‘winner’s curse’ (Sklar et al., 2011). Thus, our statistical power in study III might have been 
overestimated, as a consequence of overestimated ORs. 
 Due to the low effect sizes in psychiatric genetics, it has been estimated that in order to 
detect risk variants at a genome-wide level in case-control studies, even more subjects are 
needed than those included in PGC BD mega-analysis, which might also be underpowered 
(Sklar et al., 2011). In this perspective, investigating a phenotype with substantially higher 
effect size would require a much smaller number of subjects. Endophenotype analyses are 
suggested as potentially promising in this respect, as genetic risk variants are closer to 
endophenotypes than to the clinical phenotypes. Thus, our fourth study might have had higher 
statistical power than the former three, although there is no available output in terms of effect 
size for this study. We also lack information on the nature of the relationship between fMRI 
activation (in this case in the amygdala) and the clinical BD phenotype; reported 
abnormalities may result from clinical features as well as from genetic variation. Further, the 
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CACNA1C risk variant in study IV was selected from a GWAS investigating the BD clinical 
phenotype, and it is uncertain whether the most significant variants from such a study are 
more specific at phenoptype or endophenotype level.
As for multiple testing correction, which represents a particular challenge in GWA 
studies, this was addressed with Bonferroni correction in study II and III, and with the above-
mentioned MAX method in study I. In study IV, Family-wise error for the respective ROI 
(amygdalae) was applied as part of the SPM2 software. 
7.3 Implications and future research 
The overall implication of the findings in this dissertation is the support of the understanding 
of BD as a highly heritable and polygenic disorder, where each variant has a small effect, and 
must interact with other variants in order to give rise to the disease. Moreover, the current 
works support that most previous studies are probably underpowered, of which reason several 
thousands of cases and controls are needed to detect true risk variants for BD. Of the same 
reason, replication of former findings is necessary to identify risk variants with a high level of 
certainty. In this regard, GWA studies might be hypothesis-generating and provide a basis for 
further more focused candidate gene studies, investigating specific pathways and potential 
endophenotypes. Further, despite the identification of several BD genetic risk variants in 
recent association studies, the explained variance of these variants is small (Sklar et al., 2011). 
The reason for this is most likely that many other common and rare variants each confer a 
small increase of risk for developing BD. Hence, even larger genetic association studies are 
warranted to explain a substantial part of the observed clinical variance. 
 As we still lack knowledge on the pathophysiological mechanisms underlying BD, 
several potential pathways have been explored. In this thesis we investigated DGKH and the 
lithium-sensitive phosphatidyl inositol pathway, PALB2, BRCA2 and a DNA repair and 
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impaired neurogenesis hypothesis, in addition to ANK3, CACNA1C and the ion channelopathy 
hypothesis. In the light of the findings in this thesis and recent major GWA studies, ANK3 and 
CACNA1C are likely to be true BD susceptibility genes, and ion channelopathy is the most 
probable of these pathways to increase the risk for BD. Our findings also suggest that genetic 
variants related to ion channelopathy may increase amygdala reactivity, which in turn might 
be a neurologic mechanism underpinning the clinical symptoms observed and experienced in 
BD. With regards to genetic overlap between BD and SZ, the studies in this thesis support the 
hypothesis of a partial overlap, where some genetic variants increase the risk for one 
diagnostic category or biological mechanism, while others confer susceptibility to a broad 
spectrum of neuropsychiatric disorders and potentially underlying processes. 
 In order to gain more knowledge on the genetic susceptibility and endophenotypes in 
BD, future studies should explore the genetic association with clinical phenotypes as well as 
with biological markers related to clinical symptoms. Well-powered case-control and case-
case association studies and specific diagnostic categorization might determine which genetic 
variants and pathways are associated with broad phenotypes and which are causatively 
involved in more specific phenotypic features. Larger endophenotype studies could provide 
information on how these associations at clinical phenotype level might be explained 
neurobiologically. The ultimate psychiatric translational study should have the size of the 
largest current GWA studies, with detailed information on all levels, including DNA, mRNA, 
protein structure and function, intra- and intercellular mechanisms, brain development, 
volume and function, neurocognitive functioning, environmental stressors, and detailed 
clinical information based on structured interviews and observation. This merits thorough 
description of each subject included in each study, as well as close national and international 
collaboration and sharing of data. 
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8 CONCLUSIONS 
BD is a highly heritable and polygenic disorder, but few susceptibility genes have been 
identified, probably due to the small effect size of each variant. In order to obtain sufficient 
statistical power in genetic association studies, thousands of cases and controls are needed. 
Additionally, replication studies must be performed to confirm previous findings. Recent 
GWA studies have identified genetic variants which have generated novel hypotheses, which 
are suitable for further investigation in focused candidate gene and endophenotype studies. 
The findings in this thesis make it less likely that genetic variants in DGKH are involved in 
BD pathophysiology, while it increases the possibility that PALB2, BRCA2 and impaired 
neurogenesis may play a role, and that ANK3, CACNA1C and ion channelopathy, possibly 
through increased amygdala activation, might underlie BD symptomatology. Furthermore, 
these findings support a partial genetic overlap between BD and SZ. 
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ABSTRACT 
Objectives 
Several genetic studies have implicated the CACNA1C SNP rs1006737 in bipolar disorder 
(BD) pathology. This polymorphism was recently found associated with increased 
amygdala activity in a combined sample of healthy controls and patients with BD. We 
performed a functional Magnetic Resonance Imaging (fMRI) study in a sample of BD and 
schizophrenia (SZ) cases and healthy controls to test for altered amygdala activity in 
carriers of the rs1006737 risk allele (AA/AG), and to investigate if there were differences 
across the subgroups. 
Methods 
Rs1006737 was genotyped in 250 individuals (N = 66 BD, 61 SZ and 123 healthy 
controls), all of Norwegian ethnicity, who underwent an fMRI negative faces matching 
task. Statistical tests were performed with standard fMRI tools, with a model correcting 
for sex, age, diagnostic category and medication status in the total sample, and then in 
each subgroup. 
Results 
In the total sample, carriers of the risk allele had increased activation in the left amygdala 
(x = -24, y = -2, z = -14; Z = 3.47), (Family-wise error (FWE) P = 0.026). Subgroup-
analyses showed that this effect was significant in the BD group (x = -24, y = 0, z = -14; Z 
= 3.35) (FWE P = 0.041), but not in the other subgroups. 
Conclusions 
These results strengthen the hypothesis that CACNA1C SNP rs1006737 is involved in 
amygdala activity during emotional processing. This effect seems most prominent in BD, 
which further supports that the CACNA1C effect on amygdala activity is of importance for 
BD pathophysiology. 
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INTRODUCTION 
Despite the high heritability estimates for bipolar disorder (BD), the molecular genetic and 
neurobiological mechanisms for this disorder remain poorly understood. However, recent 
large genome-wide association (GWA) studies with substantially more statistical power than 
former psychiatric genetic studies have provided evidence for new and promising candidate 
genes (1). One of the most consistent findings is related to CACNA1C (calcium channel, 
voltage-dependent, L type, alpha 1C subunit) gene variants. The CACNA1C SNP rs1006737 
was first found to be associated with BD in a combined analysis of two GWA study datasets 
(P = 3.15 x 10-6) (2). When adding a third sample, this CACNA1C SNP was significantly 
associated with BD in the combined sample of 4,387 BD cases and 6,209 healthy controls (P 
= 7.0 x 10-8, OR = 1.181) (3). Subsequent studies also reported association between 
CACNA1C and schizophrenia (SZ) (4,5) and major depressive disorder (MDD) (4,6), thereby 
supporting the hypothesis of genetic overlap between these severe psychiatric disorders. 
CACNA1C is located on chromosome 10 and encodes an alpha-1 subunit of a voltage-
dependent calcium (Cav1.2) channel. Cav1.2 channels can be found in cardiac smooth muscle, 
neuronal and endocrine cells, where they have a variety of functions including excitation-
contraction coupling, endocrine secretion and regulation of neuronal Ca2+ transients, enzyme 
activity and transcription (7,8). Mutations in CACNA1C have been found to lead to Timothy 
syndrome, a lethal disorder consisting of somatic symptoms like cardiac arrhythmia, and 
psychiatric symptoms like autism and cognitive disability (9). 
Emotional dysregulation is part of the clinical phenotype of BD and SZ, manifesting 
as mood swings as well as affect flattening. Neurobiological correlates of emotional 
dysregulation have been reported for both these disorders, in structural Magnetic Resonance 
Imaging (sMRI) and functional MRI (fMRI) analyses measuring the volume and activity of 
the limbic system. In particular, the amygdala has been extensively studied in BD. In a recent 


mega-analysis of 321 patients with bipolar I disorder and 442 healthy controls, amygdala 
volume was found to be greater in patients treated with lithium compared to controls and 
patients not treated with lithium (10). A meta-analysis comprising 65 fMRI studies of 1074 
healthy volunteers and 1040 BD cases, found evidence for amygdala over-activation in 
euthymic BD patients compared with healthy controls (11). 
With regards to the potential involvement of BD risk genes in limbic system 
dysregulation, there are reports of an association between CACNA1C SNP rs1006737 and 
amygdala activity. In a study of 64 healthy individuals, carriers of the risk allele (AA/AG) had 
increased activity in the right amygdala in a monetary reward paradigm (12). Another group 
reported enhanced activity in AA/AG individuals compared to GG individuals in the right 
amygdala during a fearful faces paradigm (N = 41 BD patients, 25 relatives and 50 healthy 
controls) (13). Thus, there is some evidence supporting the hypothesis that CACNA1C SNP 
rs1006737 affect amygdala activity during different paradigms related to limbic system 
functioning. 
Interestingly, two recent mega-analyses reported that CACNA1C was one out of three 
common genes for BD and SZ (14,1). These findings on the molecular genetic level are 
consistent with similarities in clinical and cognitive characteristics (15), and the continuum 
hypothesis for severe psychiatric disorders (16). However, to the best of our knowledge 
CACNA1C has not been investigated with fMRI in SZ. Thus, it remains unclear whether the 
effect of this gene on amygdala activity is general or confined to one or more diagnostic 
categories. 
The primary aim of the current study was to test for altered amygdala activity in 
carriers of the CACNA1C SNP rs1006737 risk allele. Secondarily, we aimed to determine the 
specificity of such associations, by testing for potential differences between healthy controls 
and patients with BD or SZ. Therefore, we measured fMRI amygdala blood-oxygen-level 
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dependence (BOLD) responses during a faces matching paradigm (17) in 250 genotyped 
individuals of Norwegian origin, including 66 BD cases, 61 SZ cases and 123 healthy control 
subjects. 
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MATERIALS AND METHODS 
Sample characteristics 
The total number of individuals in this study was 250, including 66 BD cases, 61 SZ cases 
and 123 healthy control subjects. All participants were of Norwegian origin, part of the 
ongoing TOP (Thematic Organized Psychosis) Study, and included from 2003 to 2009.  
To be included in the study, patients had to be between 18 and 65 years, have a DSM-
IV diagnosis of a bipolar spectrum or schizophrenia spectrum disorder, and be willing and 
able to provide written informed consent. Exclusion criteria were an IQ score below 70 and 
reporting a history of head injury or neurological disorder. In the healthy control group, we 
also excluded subjects if they or their close relatives had a lifetime history of a severe 
psychiatric disorder. Subjects with a history of a medical condition potentially interfering with 
brain function (hypothyroidism, uncontrolled hypertension and diabetes), and an illicit drug 
abuse/addiction diagnosis were also excluded. 
Patients were recruited from psychiatric in- and out-patient hospital units in the Oslo 
area, and had been diagnosed with bipolar I disorder (N = 30), bipolar II disorder (N = 32), 
bipolar disorder not otherwise specified (N = 4) ), schizophrenia (N =48), schizoaffective 
disorder (N = 9) or schizophreniform disorder (N = 4), according to DSM-IV using the 
Structural Clinical Interview for DSM-IV (SCID) (18). Diagnostic evaluation was performed 
by trained psychologists and psychiatrists, of whom all participated regularly in diagnostic 
meetings supervised by professors in psychiatry. Reliability measures of the diagnostic 
assessment in the TOP study were performed, and the overall agreement for the DSM-IV 
diagnostic categories tested was 82 % and the overall Kappa 0.77 (95 % CI: 0.60-0.94). 
Information on education, age of onset, number of relapses, medication status, alcohol and 
illegal substance abuse were obtained during an initial clinical interview. Neurocognitive and 
psychosocial functioning was also assessed with clinical interviews. On the day of scanning, 
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patients underwent an abbreviated re-interview including Young Mania Rating Scale (YMRS) 
(19), Inventory of Depressive Symptoms (IDS) (20) and Positive and Negative Syndrome 
Scale (PANSS) (21). For patients lacking data for this re-interview, we used data from the 
clinical interview. 
The healthy control subjects were randomly recruited from the same catchment area as 
the patients, and underwent an initial interview where demographic and clinical information 
was obtained. Clinical assessment of the patients and healthy controls participating in the 
TOP study is described in details in a previous report (22). Demographic and clinical 
characteristics are presented in Table 1. 
The Norwegian Scientific-Ethical Committees and the Norwegian Data Protection 
Agency approved the study. All subjects have given written informed consent prior to 
inclusion into the project. 
Genotyping 
Genomic DNA was extracted from whole blood. CACNA1C SNP rs1006737 was genotyped 
in the 250 subjects participating in this study using Affymetrix Gene Chip Genome-Wide 
SNP 6.0 array (AffymetrixInc, Santa Clara, CA, USA), as described in details elsewhere 
(23,24).  
Experimental paradigm 
A widely used and validated paradigm was employed to elicit amygdala reactivity (17). In this 
task participants select which of two stimuli (displayed at the bottom of the screen) matches a 
target stimulus (displayed at the top). The images displayed were either human faces 
expressing anger or fear (faces matching task) or geometrical shapes (the sensorimotor control 
task). Participants completed 4 blocks of the faces matching task, where each block consisted 
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of 6 emotion-specific face trios derived from a standard set of facial affect pictures (25). 
Interleaved between these blocks, participants completed 5 blocks of the sensorimotor control 
task. Each trial (faces or shapes) was presented for 5.4 seconds with no inter-stimulus interval, 
for a total block length of 32.6 seconds. The total paradigm lasted 310 seconds. E-prime 
software (version 1.0 Psychology Software Tools, Inc, Pittsburgh, PA, USA) controlled the 
presentations of the stimuli using VisualSystem (NordicNeuroLab, Bergen, Norway). 
Response times and accuracy were recorded through MR-compatible ResponseGrips 
(NordicNeuroLab, Bergen, Norway). Behavioural data was missing for 13 individuals. 
Image acquisition 
MRI scans were acquired on a 1.5 T Siemens Magnetom Sonata scanner (Siemens Medical 
Solutions, Erlangen, Germany) supplied with a standard head coil. Volumes (n = 152, 24 axial 
slices, 4 mm thick with 1 mm gap) covering the whole brain were acquired in the axial plane, 
using a BOLD EPI sequence (TR=2040 ms, TE=50ms, flip angle=90º, matrix 64 x 64, FOV 
192 x 192 mm). The first seven volumes were discarded. Prior to BOLD fMRI scanning, a 
sagittal T1-weighted 3D Magnetization Prepared Rapid Gradient Echo (MPRAGE) scan (TR= 
2000 ms, TE=3.9 ms, flip angle =7º, matrix 128 x 128, FOV 256 x 256 mm) was collected for 
better localization of functional data. 
fMRI data analyses 
All fMRI volumes were preprocessed and analysed with Statistical Parametric Mapping 
(SPM2) (http://www.fil.ion.ucl.ac.uk/spm) implemented in MATLAB7.1 (The Mathworks 
Inc, Natick, Massachusetts). All of the functional images were realigned to the first image in 
the time series to correct for head motion (26). All subjects moved less than 2.5 mm in any 
direction during the scan. Subsequently, the mean functional image and the anatomical image 
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were coregistered to ensure that they were aligned. The images were spatially normalized to 
the stereotactical MNI template (26), and resampled at 2x2x2 mm voxels. The images were 
smoothed using a 6 mm full width-half maximum (FWHM) isotropic kernel. Data were high-
pass filtered using a cutoff value of 128 s. The fMRI data for all subjects were first analysed 
using a single-subject fixed-effect model. The model was built by convolving boxcar 
functions for the onsets of the two different conditions (faces and figures) with a canonical 
hemodynamic response function (HRF). Individual contrast images were created by 
subtracting “figures” from “faces”.  The contrast images for faces versus figures for each 
subject were entered into a random effects statistical model. These data were analysed with a 
region of interest (ROI) approach and a pre-defined anatomical mask (bilateral amygdala) 
derived from the Wake Forest University PickAtlas for SPM2 (27).  
Statistical analysis 
For the overall sample (N = 250), we used an ANCOVA model comparing amygdala activity 
in risk-allele carriers (AA/AG) with the corresponding activity in carriers of the protective 
allele (GG), using sex, age, diagnostic category (BD, SZ, healthy control) and medication 
status  as covariates. Medication status was dichotomised for the categories Antipsychotics, 
Lithium, Antidepressants, Anticonvulsives and Hypnotics. We also tested for potential 
specific effects in each diagnostic subcategory, for genotype x diagnosis interactions, and for 
effect of diagnostic category on amygdala activity. Findings were corrected for multiple 
testing with Family-Wise Error (FWE) within the respective ROI.
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RESULTS 
Behavioural results 
Genotype group and diagnosis did not influence the accuracy rate significantly. The mean 
response time (RT) was significantly longer for individuals in the BD group (RT = 1255 
milliseconds (ms)) and SZ group (RT = 1231 ms) than those in the healthy control group (RT 
= 1065 ms) (P < 0.001), but did not differ significantly with respect to genotype group. For 
details, see Table 1. 
Sociodemographic and clinical results  
Carriers of the risk allele did not differ significantly from the GG homozygotes with respect to 
demographical variables within the total sample or any of the diagnostic groups (Table 1). 
Further, the clinical characteristics did not differ between genotype groups, except that risk 
allele carriers in the total patient sample had significantly lower Global Assessment of 
Functioning-symptom score (GAF-S) than those with the GG genotype (P = 0.01). However, 
this was not seen in the subgroups, and was probably due to a higher frequency of the risk 
allele in the SZ group (43/61 (70.5 %)) compared to the BD group (34/66 (51.5 %)). For 
details regarding results across diagnostic categories, see Table 1. 
fMRI results 
The fMRI results are shown in Table 2 and Figure 1. In the total sample (N = 250), carriers of 
the CACNA1C SNP rs1006737 risk allele (AA/AG) showed significantly increased activation 
in the left amygdala (x = -24, y = -2, z = -14; Z = 3.47; cluster-size = 72), with an FWE-
corrected P-value of 0.026. The risk allele was also significantly associated with enhanced 
activity in the left amygdala (x = -24, y = 0, z = -14; Z = 3.35; cluster-size = 91) in the BD 
subgroup (FWE-corrected P = 0.041). There were also AA/AG associated activations in the 
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right amygdala in the total sample (x = 26, y = 0, z = -16, Z = 2.65, cluster-size = 32) and in 
the BD subgroup (x = 22, y = 0, z = -20, Z = 2.54, cluster-size = 61), but these did not reach 
significance level. There were no significant findings in the SZ subgroup or the healthy 
control group, but the activation patterns had the same direction in all subgroups, of which 
reason there was no significant genotype x diagnosis interaction effect between BD and the 
other subgroups. Furthermore, there was no significant effect of diagnosis on amygdala 
activity. 
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DISCUSSION 
The main finding in this study was an enhanced activation in the left amygdala in carriers of 
the CACNA1C SNP rs1006737 risk allele. This effect was also significant in the BD 
subgroup, but did not reach significance level in the SZ or healthy control subgroup. 
To the best of our knowledge, no studies of amygdala activity and CACNA1C
polymorphisms have investigated the specificity in BD. We found a significant association in 
the BD subgroup, with an even larger cluster size (k = 91) than in the total sample (k = 72. 
The fact that the most significant association was found in the BD sample, might indicate a 
stronger effect for this CACNA1C polymorphism in amygdala in BD than in SZ and healthy 
controls, although there was no significant diagnosis x genotype interaction. Interestingly, 
recent GWA studies found the presently investigated SNP to be significantly associated with 
BD (P =1.7 x 10-5; OR = 1.11) as well as SZ (P = 1.2 x 10-6; OR = 1.11) (14,1). This suggests 
susceptibility of similar effect sizes on the clinical phenotype level, while the present results 
indicate different specificity with regards to amygdala activity. This hypothesis is 
underpinned by the fact that other genes involved in calcium channel regulation have been 
found to be associated with neurological disorders such as migraine, ataxia and epilepsy (28). 
Thus, genetically conditioned calcium channel dysregulation might be a common mechanism 
increasing the risk for developing several neuropsychiatric disorders, by affecting various 
brain structures including amygdala. 
The current finding that CACNA1C SNP rs1006737 risk allele is associated with 
increased amygdala activity is in line with two previous studies (13,12). One of the studies 
found that individuals with the risk allele have increased activity in the right amygdala during 
a reward paradigm (12), and the other reported increased activity in the right amygdala during 
a fear-face paradigm (13). In the current study, we found significantly enhanced activation in 
the left amygdala during a negative faces paradigm. But there was also nominally 
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significantly increased activity in the right amygdala in our sample (Table 2). Taken together, 
previous and present results suggest that carriers of the CACNA1C SNP rs1006737 A allele 
might have increased activity in amygdala bilaterally during processing of emotional and 
reward stimuli. 
As this increased activity has been reported for different paradigms, it is uncertain 
whether these responses reflect different neurobiological pathways, like positive and negative 
conditioning, or whether this enhanced response to emotional stimuli with different valences 
indicates that amygdala is occupied with relevance detection in general, rather than with only 
fear-related or reward-related information (29,30). Furthermore, it remains unclear if 
amygdala over-activation is a cause or secondary effect of disease-related  processes, and how 
this over-activation is causally related to prefrontal functioning, as there is evidence of 
reduction of volume (31) as well as activity (11) in the prefrontal cortex in BD. It is possible 
that enhanced amygdala activation is a primary biological feature of BD, but it may also be a 
consequence of decreased prefrontal inhibition, which in turn may result from 
neurodevelopmentally conditioned prefrontal volume reduction. A combination of these two 
neurobiological processes should also be taken into consideration, and the relative 
contribution could be different in SZ and BD. Additionally, we lack knowledge on how 
environmental factors may modulate the neurobiological aspects of severe psychiatric 
disorders like BD and SZ. Pharmacological treatment could also affect this relationship, but 
we found no effect of ongoing treatment in the current sample. 
Genetic variations in CACNA1C have been shown to imply additional psychiatric 
manifestations to those observed in BD and SZ. Patients with the above-mentioned Timothy 
syndrome are characterized by symptoms like autism and cognitive disability. In a proposed 
model of a spectrum of psychiatric disorders with autism in the neurodevelopmental end and 
MDD in the affective end (16), it is possible that polymorphisms in or around the CACNA1C
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gene could increase the risk of developing less severe conditions than those observed in 
Timothy syndrome, like BD and SZ. This is further supported by the fact that rs1006737 is 
situated in one of the introns of CACNA1C, thus probably affecting pathophysiological 
pathways related to these disorders by regulating the expression of the protein, and not by 
altering the structure, as is the case with the de novo mutations in Timothy syndrome, which 
are located in one of the exons (32). 
As for the potential pharmacological consequences of the association between 
CACNA1C and BD and SZ, calcium channel blockers have been studied in affective disorders 
and substance abuse/dependence (33). Some promising preliminary results have been reported 
for dihydropyridine-based blockers that bind specifically to Cav1.2 channels in the treatment 
of BD, but more studies are needed (34). Future pharmacological studies could investigate the 
potentially modulating effect of calcium channel blockers on the endophenotype level, like for 
example amygdala activity in BD. 
Taken together, the current findings provide evidence that the CACNA1C SNP 
rs1006737 is involved in neurobiological processes underpinning severe psychiatric disorders, 
most pronounced in BD. The present study further strengthens the hypothesis that these 
mechanisms may include increased amygdala activity.
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